



CURRICULUM VITAE
Patrick H. Nachman, MD

PROFESSIONAL ADDRESS

Division of Renal Diseases and Hypertension
717 Delaware St SE, 350 Office
Minneapolis, MN 55414
Phone: 612-624-9444
Fax: 612-626-3840
pnachman@umn.edu

IDENTIFYING INFORMATION

Education

Degree	Institution	Date Degree Granted
B.S.	American University of Beirut, Beirut, Lebanon	1983
M.D.	Boston University School of Medicine, Boston, Massachusetts	1989
Internal Medicine Resident	University of North Carolina, Chapel Hill, NC	1990
Nephrology Research Fellowship	University of North Carolina, Chapel Hill, NC	1995
Nephrology Fellowship	University of North Carolina, Chapel Hill, NC	1996

Certifications, Licenses

Minnesota State Medical Board	2017-present
American Board of Internal Medicine – Nephrology	1996-present
American Board of Internal Medicine	1992-2002
North Carolina State Medical Board	1991-present

Academic Appointment

University of Minnesota, Division of Renal Diseases and Hypertension Minneapolis, MN Professor	2018-present
University of North Carolina, Division of Nephrology and Hypertension Chapel Hill, NC Marion Stedman Covington Distinguished Professor	2016-2018
University of North Carolina, Division of Nephrology and Hypertension Chapel Hill, NC Professor	2009-2018

University of North Carolina, Division of Nephrology and Hypertension
Chapel Hill, NC
Associate Professor 2003-2009

University of North Carolina, Division of Nephrology and Hypertension
Chapel Hill, NC
Assistant Professor 1996-2003

Academic Administrative Appointments

University of Minnesota, Division of Renal Diseases and Hypertension
Minneapolis, MN
Division Director 2018-present

University of North Carolina Kidney Center
Chapel Hill, NC
Deputy Director 2015-2018

Consulting Positions

Cardiovascular and Renal Drugs Advisory Committee: Food and Drug
Administration 2016-present

**HONORS AND AWARDS FOR RESEARCH WORK, TEACHING, PUBLIC ENGAGEMENT,
AND SERVICE**

External Sources

Best Doctors in America 2008-present
UNC Division of Nephrology and Hypertension Maestro Award 2018
UNC Health Care and Faculty Physicians Award – Carolina Care Excellence 2015
Internal Medicine Housestaff Faculty Award 2007
Boston University School of Medicine, Dr. Samuel Poplack Student Award 1989
for superior clinical competence and excellence in patient care
B.S. degree with Distinction, American University of Beirut 1983

RESEARCH AND SCHOLARSHIP

Grants and Contracts

External Sources

Current External Sources

1.
Role: Protocol Chair
Name of PI: Gerald NEPOM. Immune Tolerance Network
Grant Number (If Applicable): 5UM1AI109565-05 (Nepom)
External Granting Agency/Sponsor: NIH/ Benaroya Research Institute at Virginia Mason

Grant/Project Title: Immune Tolerance Network. A Phase II, Double-Blind, Randomized, Placebo-Controlled Trial of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (**Protocol ITN080AI**)

Project Dates: 02/05/2018 – 01/31/2021
Total Revenue Received to Date: \$20,956
% Effort/Salary Support: 1.2 calendar

2.

Role: Site Principal investigator
Name of PI (if not the candidate):
Grant Number (If Applicable): CL011-140
Granting Agency: ChemoCentryx Inc
Grant Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)
Project Dates: 03/01/2018 – 12/31/2020
Direct Costs Per Year: \$19,062.00
% Effort/Salary Support: Per patient support

3.

Role: Site Principal investigator
Name of PI (if not the candidate):
Grant Number (If Applicable): CL012-140
Granting Agency: ChemoCentryx Inc
Grant Title: An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
Project Dates: 03/01/2018 – 12/31/2020
Direct Costs Per Year:
% Effort/Salary Support: Per patient support

4.

Role: Site Principal Investigator
Name of PI (if not the candidate):
Grant Number (If Applicable): IFX-1-P2.6
Granting Agency: InflaRX GmbH
Grant Title: IFX-1-P2.6: A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Phase II Study to Investigate the Safety and Efficacy of Two Different Dose Regimens of IFX-1 as Add-on to Standard of Care in Subjects with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Project Dates: 6/01/2018 – 12/31/2021
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support: 1

5.

Role: Site Principal Investigator
Name of PI (if not the candidate):
Grant Number (If Applicable): AUR-VCS-2017-03
Granting Agency: Aurinia Pharmaceuticals, Inc.

Grant Title: AUR-VCS-2017-03: An Open Label, Dose Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis.

Project Dates: 6/01/2018 – 12/31/2021

Direct Costs Per Year: Per Patient Support

% Effort/Salary Support: 1

6.

Role: Site Principal Investigator

Name of PI (if not the candidate):

Grant Number (If Applicable): OMS721-IGA-001

Granting Agency: Omeros Corporation

Grant Title: OMS721-IGA-001: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA)

Nephropathy (ARTEMIS IGAN)

Project Dates: 2/01/2018 – 12/31/2023

Direct Costs Per Year: Per Patient Support

% Effort/Salary Support: 1

7.

Role: Site Principal Investigator

Name of PI (if not the candidate):

Grant Number (If Applicable):

Granting Agency: Genzyme/Sanofi

Grant Title: Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Project Dates: 4/02/2019 –

Direct Costs Per Year: Per Patient Support

% Effort/Salary Support: 1

Past External Sources

1.

Role: Principal investigator for subproject IV, Co-PI, Co-investigator)

Name of PI (if not the candidate): Falk, Ronald J.

Grant Number (If Applicable): P01 DK058335

External Granting Agency/Sponsor: NIH/NIDDK

Grant/Project Title: ANCA Glomerulonephritis: From Molecules to Man

Project Dates: 7/1/2000 – 6/30/2020

Direct Costs Per Year: \$1,094,026

% Effort/Salary Support: 10%

2.

Role: Co-investigator

Name of PI (if not the candidate): Falk, Ronald J.

Grant Number (If Applicable): UM1 DK100867

Granting Agency: NIH/NIDDK

Grant Title: GDCN Clinical Center-Advancing Clinical Research in Primary Glomerular Diseases (CureGN)

Project Dates: 7/1/2014 – 7/1/2019

Direct Costs Per Year: \$553,079

% Effort/Salary Support: 20%

3.

Role: Co-investigator

Name of PI (if not the candidate): Kretzler, Matthias

Grant Number (If Applicable):

Granting Agency: ORD/NIDDK/UMich/NephCure

Grant Title: NEPhrotic Syndrome sTudy NEtwork (NEPTUNE): **Steering Committee award**

Project Dates: 7/1/2014 – 6/30/2019

Direct Costs Per Year:

% Effort/Salary Support: 5%

4.

Role: Co-investigator

Name of PI (if not the candidate): Kretzler, Matthias

Grant Number (If Applicable): 1U54DK083912-01

Granting Agency: Office of Rare Diseases/NIDDK/NIH

Grant Title: NEPhrotic Syndrome sTudy NEtwork (NEPTUNE): Site PI award

Project Dates: 9/1/2014-6/30/2019

Direct Costs Per Year:

% Effort/Salary Support: per patient support

5.

Role: Faculty / Mentor

Name of PI (if not the candidate): Falk, Ronald J.

Grant Number (If Applicable): DK007750

Granting Agency: NIH/NIDDK

Grant Title: Renal Epidemiology Training Grant

Project Dates: 1/1/1999 – 9/1/2018

Direct Costs Per Year:

% Effort/Salary Support: 0

6.

Role: Project Leader

Name of PI (if not the candidate): Falk, Ronald J.

Grant Number (If Applicable): 2P01DK058335-06

External Granting Agency/Sponsor: NIH/NIDDK

Grant/Project Title: ANCA Glomerulonephritis: From Molecules to Man

Project Dates: 9/1/2000 – 8/30/2015

Total Revenue Received to Date: \$148,226.00

% Effort/Salary Support: 20%

7.

Role: Co-investigator

Name of PI (if not the candidate): Falk, Ronald J.

Grant Number (If Applicable): 2P01DK058335-06

Granting Agency: NIH/NIDDK
Grant Title: NIH Core A: Clinical Core
Project Dates: 9/1/2000 – 8/30/2015
Direct Costs Per Year: \$151,945.00
% Effort/Salary Support: 5%

8.

Role: Site principal investigator
Name of PI (if not the candidate): Kretzler, Matthias
Grant Number (If Applicable):
Granting Agency: ORD/NIDDK/UMich/NephCure
Grant Title: NEPhrotic Syndrome sTUDy NEtwork (NEPTUNE): Clinical part
Project Dates: 07/01/2010 – 06/30/2020
Direct Costs Per Year: per patient support
% Effort/Salary Support: 5%

9.

Role: Project Leader
Name of PI (if not the candidate): Kretzler, Matthias
Grant Number (If Applicable): Granting Agency: Office of Rare Diseases/NIDDK/NIH
Grant Title: NEPhrotic Syndrome sTUDy NEtwork (NEPTUNE): **Steering Committee award**
Project Dates: 07/01/2010 – 06/30/2020
Direct Costs Per Year:
% Effort/Salary Support: 10%

10.

Role: Mentor
Name of PI (if not the candidate): Falk, Ronald J.
Grant Number (If Applicable): DK007750
Granting Agency: NIH/NIDDK
Grant Title: Renal Epidemiology Training Grant
Project Dates: 3/1/1999 – 2/28/2014
Direct Costs Per Year: \$258,703.00
% Effort/Salary Support: 0

11.

Role: Site principal investigator
Name of PI (if not the candidate): Merkel, Peter
Grant Number (If Applicable):
External Granting Agency/Sponsor:
Grant/Project Title: Plasma exchange (PLEX) and glucocorticoids for treatment of ANCA-associated vasculitis (PEXIVAS)
Project Dates: 4/1/2010 – 3/31/2017
Total Revenue Received to Date: \$43,193.00
% Effort/Salary Support: Per patient support

Past Business and Industry (Clinical) Trials

1.

Role: UNC PI -investigator)
Name of PI (if not the candidate): Torres, Vicente
Grant Number (If Applicable): Otsuka 210
Granting Agency: Otsuka Pharmaceutical
Grant Title: A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to UNC PI
Project Dates: 9/30/2014 – 7/30/2018
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support: 1

2.

Role: UNC Principal investigator
Name of PI (if not the candidate): Torres, Vicente
Grant Number (If Applicable): Otsuka 211
Granting Agency: Otsuka Pharmaceutical
Grant Title: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/d, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease
Project Dates: 09/30/2014-07/01/2018
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support: 1

3.

Role: UNC Principal investigator
Name of PI (if not the candidate): Peter Merkel
Grant Number (If Applicable): ISRCTN07757494
Granting Agency: European Vasculitis Study Group (EUVAS) and the Vasculitis Clinical Research Consortium (VCRC)
Grant Title: Plasma exchange and glucocorticoid dosing in the treatment of ANCA-associated vasculitis: an international randomized controlled trial. UNC Site PI. This is a multicenter international randomized controlled trial to evaluate the role of plasma exchange and glucocorticoid dosing in the induction treatment of patients with severe ANCA associated vasculitis.
Project Dates: 7/1/2010- 7/1/2016
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support:

4.

Role: UNC site Principal Investigator
Name of PI (if not the candidate): Debbie S. Gipson
Grant Number (If Applicable):
Granting Agency: Patient-centered Outcomes Research Institute (PCORI)
Grant Title: Development of a Decision Support Tool for Nephrotic Syndrome Management
Project Dates: 10/23/2012 – 13/31/2013
Direct Costs Per Year:
% Effort/Salary Support:

5.

Role: UNC Site Principal Investigator
Name of PI (if not the candidate):
Grant Number (If Applicable):

Granting Agency: North American Sponsor: University of Pennsylvania (US and Canada)
Grant Title: RITAZAREM: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis
Project Dates: 09/01/201-08/31/2018
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support:

6.

Role: Principal Investigator
Name of PI (if not the candidate):
Grant Number (If Applicable): CL
Granting Agency: ChemoCentryx Inc
Grant Title: An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with IgA Nephropathy on Stable RAAS Blockade
Project Dates: 12/01/2014 – 12/01/2017
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support: 1%

7.

Role: Investigator status (Principal investigator, Co-PI, Co-investigator)
Name of PI (if not the candidate):
Grant Number (If Applicable): CL003_168
Granting Agency: ChemoCentryx Inc
Grant Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Project Dates: 10/13/2014 – 10/01/2017
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support: 1%

8.

Role: Principal Investigator
Name of PI (if not the candidate):
Grant Number (If Applicable): GW856553
Granting Agency: Glaxo Smith Kline
Grant Title: Study of Losmapimod to Reduce Proteinuria in Corticosteroid or Calcineurin Inhibitor Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Project Dates: 10/01/2013 – 10/01/2016
Direct Costs Per Year: Per Patient Support
% Effort/Salary Support: 1%

9.

Role: Site Principal Investigator
Name of PI (if not the candidate): Vicente Torres
Grant Number (If Applicable):
Granting Agency: Otsuka Pharmaceutical
Grant Title: A phase 3, multicenter, double blind, placebo-controlled, parallel-arm trial to determine long-term safety and efficacy of oral tolvaptan tablet regimens in adult subjects with autosomal dominant polycystic kidney disease.
Project Dates: 08/01/2007 – 08/01/2012
Direct Costs Per Year: Per Patient Support

% Effort/Salary Support: 1%

10.

Role: Site Principal Investigator

Name of PI (if not the candidate): Vicente Torres

Grant Number (If Applicable):

Granting Agency: Otsuka Pharmaceutical

Grant Title: Multi-center, Open-label, Phase III Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Project Dates: 11/29/2010 – 11/29/2014

Direct Costs Per Year: Per patient support

% Effort/Salary Support:

11.

Role: Site Principal Investigator

Name of PI (if not the candidate): Vicente Torres

Grant Number (If Applicable):

Granting Agency: Otsuka Pharmaceutical

Grant Title: A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease .

Project Dates: 09/30/2014 – 09/30/2018

Direct Costs Per Year:

% Effort/Salary Support: Per patient support

12.

Role: Site Principal Investigator

Name of PI (if not the candidate): Vicente Torres

Grant Number (If Applicable):

Granting Agency: Otsuka Pharmaceutical

Grant Title: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease

Project Dates: 09/30/2014 – 09/30/2018

Direct Costs Per Year:

% Effort/Salary Support: Per patient support

13.

Role: Principal Investigator

Name of PI (if not the candidate):

Grant Number (If Applicable): Protocol CL003_168

Granting Agency: ChemoCentryx Inc

Grant Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Project Dates: 10/13/2014 – 10/13/2017

Direct Costs Per Year:

% Effort/Salary Support: Per patient support

14.

Role: Investigator status (Principal investigator, Co-PI, Co-investigator)

Name of PI (if not the candidate):

Grant Number (If Applicable):

Granting Agency: ChemoCentryx Inc

Grant Title: An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with IgA Nephropathy on Stable RAAS Blockade

Project Dates: 12/08/2014 – 12/08/2017

Direct Costs Per Year:

% Effort/Salary Support: Per patient support

Publications

1. Wu EY, McInnis EA, Boyer-Suavet S, Mendoza CE, Aybar LT, Kennedy KB, Poulton CJ, Henderson CD, Hu Y, Hogan SL, Hu P, Xiao H, **Nachman PH**, Jennette JC, Falk RJ, Bunch DO. Measuring circulating complement activation products in myeloperoxidase and proteinase 3 antineutrophil cytoplasmic antibody vasculitis. *Arthritis Rheumatol* 2019, [Epub ahead of print] PubMed PMID 31215772
2. Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, **Nachman P**, Esnault V, Seitz-Polski B. Rituximab bioavailability in primary membranous nephropathy. *Nephrol Dial Transplant*. 2019 [Epub ahead of print] PubMed PMID: 30929012.
3. Hogan SL, **Nachman PH**, Poulton CJ, Hu Y, Blazek LN, Free ME, Jennette JC, Falk RJ. Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Kidney Int Rep*. 2019 Jan 28;4(4):551-560.
4. Troost JP, Gipson DS, Carlozzi NE, Reeve BB, **Nachman PH**, Gbadegesin R, Wang J, Modersitzki F, Massengill S, Mahan JD, Liu Y, Trachtman H, Herreshoff EG, DeWalt DA, Selewski DT. Using PROMIS® to create clinically meaningful profiles of nephrotic syndrome patients. *Health Psychol*. 2019 May;38(5):410-421.
5. Canetta PA, Troost JP, Mahoney S, Kogon AJ, Carlozzi N, Bartosh SM, Cai Y, Davis TK, Fernandez H, Fornoni A, Gbadegesin RA, Herreshoff E, Mahan JD, **Nachman PH**, Selewski DT, Sethna CB, Srivastava T, Tuttle KR, Wang CS, Falk RJ, Gharavi AG, Gillespie BW, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Guay-Woodford LM, Reeve B, Gipson DS; CureGN Consortium. Health-related quality of life in glomerular disease. *Kidney Int*. 2019 Feb 27. Epub ahead of print
6. Lardinois OM, Deterding LJ, Hess JJ, Poulton CJ, Henderson CD, Jennette JC, **Nachman PH**, Falk RJ. Immunoglobulin G from Patients with ANCA-Associated Vasculitis are Atypically Glycosylated in Both the Fc and Fab Regions and the Relation to Disease Activity. *PLOS One* 2019, Feb 28;14(2):e0213215
 Impact Factor: 2.766
 Times Cited:
 Role: Intellectual content, Manuscript preparation, Manuscript editing, Manuscript review
7. Thompson A, Carroll K, Inker L, Floege J, Perkovic V, Boyer S, Major R, Schimpf J, Barratt J, Cattran DC, Gillespie B, Kausz A, Mercer A, Reich HN, Rovin B, West M, **Nachman PH**. Proteinuria Reduction as a Surrogate Endpoint in Trials of IgA Nephropathy. *Clin J. Am Soc Nephrol*. 2019. Epub ahead of print
 Impact Factor: 5.835
 Times Cited:
 Role: Intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review.
8. Floege J, Barbour S, Cattran DC, Hogan JJ, **Nachman PH**, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayr WC, Rovin BH for conference participants. Management and Treatment of Glomerular Diseases (Part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2019; 95:268-280.
 Impact Factor: 8.395

Times Cited:

Role: Manuscript preparation, editing, review.

9. Reynolds ML, **Nachman PH**, Mooberry MJ, Crona DJ, Derebail VK. Recurrent Venous Thromboembolism in Primary Membranous Nephropathy Despite Direct Xa Inhibitor Therapy. *J Nephrol* 2018 ;
 Impact Factor:
 Times Cited:
 Role: Report concept, manuscript preparation, editing, review
10. Mariani L, Bomback A, Canetta, P, Flessner M, Helmuth M, Hladunewich M, Hogan J, Kiryluk K, **Nachman P**, Nast C, Rheault M; Rizk D, Trachtman H, Wenderfer S, Bowers C, Hill-Callahan P, Marasa M, Poulton C; Revell A, Vento S, Barisoni L, Cattran D, D'Agati V; Jennette JC, Klein J, Laurin LP, Twombly K, Falk R, Gharavi A, Gillespie B, Gipson D, Greenbaum L, Holzman L, Kretzler M, Robinson B, Smoyer W, Guay-Woodford L. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. *Am J Kidney Dis* 2018 Accepted for publication
 Impact Factor: 3.59
 Times Cited: 0
 Role: Study concept, Study design, Manuscript editing, Manuscript review
11. **Nachman PH**. The Kidney Health Initiative and IgAN. *Kidney Dis* 2018;4:175-176
 Impact factor:
 Times Cited
 Role: Intellectual content, Conducted study research, Manuscript preparation, Manuscript editing, Manuscript review
12. **Nachman PH**. Repeat kidney biopsy for lupus nephritis: an important step forward. *Kidney Int* 2018; 94(4):659-661
 Impact factor: 8.429
 Role: Intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
13. Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Bou Matar R, Cai Yi, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, **Nachman PH**, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombly K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K, on behalf of the CureGN Consortium Clinical Characteristics and Treatment Patterns of Children and Adults with IgA Nephropathy or IgA Vasculitis: Findings from the CureGN Study. *Kidney International Reports* 2018.
 Impact Factor:
 Times Cited: 0
 Role: Study concept, Study design, Intellectual content, Manuscript editing, Manuscript review
14. Mahoney SL, **Nachman PH**. Persistent Hematuria in ANCA Vasculitis: Ominous or Innocuous? *Clin J Am Soc Nephrol*. 2018; 13(2):201-202. PMID:29371338
 Impact Factor: 5.355

Times Cited: 0

Role: Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review

15. Troost JP, Trachtman H, **Nachman PH**, Kretzler M, Spino C, Komers R, Tuller S, Perumal K, Massengill SF, Kamil ES, Oh G, Selewski DT, Gipson P, Gipson DS. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. *Clin J Am Soc Nephrol*. 2017 [Epub ahead of print] PubMed PMID: 29167190.
Impact Factor: 5.355
Times Cited: 0
Role: Study concept, Manuscript preparation, Manuscript editing, Manuscript review

16. Jennette JC, **Nachman PH**. ANCA Glomerulonephritis and Vasculitis. *Clin J Am Soc Nephrol*. 2017;12:1680-1691.
Impact Factor: 5.355
Times Cited: 2
Role: Manuscript preparation, Manuscript editing, Manuscript review

17. O'Shaughnessy MM, Jobson MA, Sims K, Liberty AL, **Nachman PH**, Pendergraft WF. Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina. *Am J Nephrol*. 2017;45:442-451.
Impact Factor: 2.796
Times Cited: 2
Role: Study concept, Study design, intellectual content, Manuscript preparation, Manuscript editing, Manuscript review

18. Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, **Nachman PH**, Falk RJ, Charles Jennette J. Interstitial lung disease in ANCA vasculitis. *Autoimmun Rev*. 2017 Jul;16(7):722-729. PMID: 28479484.
Impact Factor: 6.853
Times Cited: 4
Role: Study concept, Study design, Manuscript editing, Manuscript review

19. Beanlands H, Maione M, Poulton C, Herreshoff E, Hladunewich MA, Hailperin M, Modes MM, An L, Nunes JW, Trachtman H, **Nachman P**, Gipson DS. Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome. *Nephrol Dial Transplant*. 2017;32(suppl_1):i98-i105. PMID: 28391342
Impact Factor: 3.938
Times Cited: 0
Role: Study concept, Study design, Manuscript editing, Manuscript review

20. Hladunewich MA, Beanlands H, Herreshoff E, Troost JP, Maione M, Trachtman H, Poulton C, **Nachman P**, Modes MM, Hailperin M, Pitter R, Gipson DS. Provider perspectives on treatment decision-making in nephrotic syndrome. *Nephrol Dial Transplant*. 2017 Jan 1;32(suppl_1):i106-i114. PMID: 28391336.
Impact Factor: 3.938
Times Cited: 0
Role: Study concept, Study design, Manuscript editing, Manuscript review

21. Laurin LP, **Nachman PH**, Foster BJ. Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature. *Can J Kidney Health Dis*. 2017;4:2054358117692559.

Impact Factor:

Times Cited: 1

Role: Study concept, Developed Study design, Manuscript editing, Manuscript review

22. Brown LC, Jobson MA, Payan Schober F, Chang EH, Falk RJ, **Nachman PH**, Pendergraft WF. The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy. *Am J Nephrol.* 2017;45:365-372.

Impact Factor: 2.796

Times Cited: 0

Role: Study concept, Study design, Manuscript preparation, Manuscript editing, Manuscript review

23. Payan Schober F, Jobson MA, Poulton CJ, Singh HK, Nickeleit V, Falk RJ, Jennette JC, **Nachman PH**, Pendergraft III WF. Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis. *Am J Nephrol.* 2017;45:248-256.

Impact Factor: 2.796

Times Cited: 0

Role: Study concept, Study design, Manuscript preparation, Manuscript editing, Manuscript review

24. Laurin LP, Gasim AM, Derebail VK, McGregor JAG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, **Nachman PH**. Renal survival in patients with collapsing compared with not otherwise specified focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol* 2016, 11:1752-1759

Impact Factor: 5.355

Times Cited: 0

Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review

25. Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, **Nachman PH**. Patients with Primary Membranous Nephropathy Are at High-risk of Cardiovascular Events. *Kidney Int* 2016;89:1111-8

Impact Factor: 9.119

Times Cited: 8

Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review

26. Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, **Nachman PH**. Treatment with glucocorticoids or calcineurin inhibitors in primary focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol.* 2016;11:386-94

Impact Factor: 5.355

Times Cited: 10

Role: Developed Study concept, Developed Study design, Defined intellectual content, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review

27. Wu EY, Pendergraft WF III, **Nachman PH**. Management of Vasculitic Glomerulonephritis. *Current Treatment Options in Rheumatology.* 2016;2(2):196-212

Impact Factor: NA

Times Cited: NA

Role: literature research, Manuscript preparation, Manuscript editing, Manuscript review

28. Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, **Nachman PH**, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-asado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M. Complete Remission in the Nephrotic Syndrome Study Network. *Clin J Am Soc Nephrol*. 2016 Jan 7;11(1):81-9.
Impact Factor: 5.355
Times Cited: 14
Role: Study concept, Study design, Manuscript editing, Manuscript review
29. Pendergraft WF, **Nachman PH**. Recent Pathogenetic Advances in ANCA Vasculitis. *Presse Medicale* 2015, 44(6 Pt 2):e223-9
Impact Factor: NA
Times Cited: 3
Role: Literature research, Manuscript preparation, Manuscript editing, Manuscript review
30. Thompson A, Cattran DC, Blank M, **Nachman PH**. Surrogate Endpoints in Primary Membranous Nephropathy: a Critical Evaluation of Complete and Partial Remission. *J Am Soc Nephrol* 2015;26:2930-7
Impact Factor: 9.423
Times Cited: 13
Role: Study concept, Study design, Intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
31. Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, **Nachman PH**, Pendergraft WF, McGregor JAG. Gleaning relapse risk from B cell phenotype: decreased CD5⁺ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis. *Ann Rheum Dis* 2015 ;74(9):1784-6.
Impact Factor: 10.7
Times Cited: 6
Role: Study design, Data analysis, Manuscript editing, Manuscript review
32. McGregor JAG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, **Nachman PH**, Falk RJ, Hogan SL. Adverse Events and Infectious Burden, Microbes and Temporal Outline from ImmunosuppressiveM Therapy in Antineutrophil Cytoplasmic Antibody Associated Vasculitis with Native Renal Function. *Nephrol Dial Transplant* 2015, Suppl 1:i171-i181.
Impact Factor: 3.938
Times Cited: 12
Role: Study design, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
33. Mcgregor JAG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez, R, Kidd JM, Katsanos SL, Bunch DO, **Nachman PH**, Falk RJ. Rituximab as an Immunosuppressant in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis. *Nephrol Dial Transplant* 2015, Suppl 1:i123-i131.
Impact Factor: 3.938
Times Cited: 7
Role: Study concept, Study design, Defined intellectual content, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
34. **Nachman PH** and Glasscock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program. (NephSAP). *J Am Soc Nephrol*. NephSAP, 2014 online publication.

Impact Factor: 9.423

Times Cited: NA

Role: Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review

35. Lee T, Gasim A, Derebail VK, Yunro C, McGregor JA, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ and **Nachman PH**. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. *Clin J Am Soc Nephrol*. 2014;9:905-13.
Impact Factor: 5.355
Times Cited: 22
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
36. Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour S, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney S, Jennette JC, Hogan SL, Falk RJ, Cattran DC, Reich HN, and **Nachman PH**. Prophylactic anticoagulation in patients with membranous nephropathy: A Decision Analysis. *Kidney Int*. 2014;85: 1412-20. <https://www.med.unc.edu/gntools/>
Impact Factor: 9.119
Times Cited: 21
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
37. Clark W, Derebail VK and **Nachman PH**. Co-editor, Nephrology Self Assessment Program: Vaso-occlusive Diseases of the Kidney. *J Am Soc Nephrol*. NephSAP, 2014 online publication.
Impact Factor: 9.423
Times Cited: NA
Role: Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
38. Laurin LP, **Nachman PH**, Desai PC, Ataga KI, Derebail VK. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. *Nephrol Dialysis Transplant*. 2014;29: 1211-8.
Impact Factor: 3.938
Times Cited: 23
Role: Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
39. Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, McGregor J, Burkart M, Hogan SL, Hu Y, Winnik W, **Nachman PH**, Stegeman CA, Niles J, Heeringa P, Kitching AR, Holdsworth S, Jennette JC, Preston GA, Falk RJ. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. *J Clin Invest*. 2013;123(4):1773-83.
Impact Factor: 14.415
Times Cited: 108
Role: Data analysis, Manuscript editing, Manuscript review
40. Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, **Nachman PH**. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. *Clin J Am Soc Nephrol*. 2013 Mar;8(3):382-91.
Impact Factor: 5.355
Times Cited: 44
Role: Guarantor of integrity of entire study, Study concept, Study design, Defined intellectual content, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review

41. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, **Nachman PH**, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. *Kidney Int.* 2013;83(4):749-56.
Impact Factor: 9.119
Times Cited: 69
Role: Study concept, Study design, Manuscript editing, Manuscript review
42. Poulton CJ, **Nachman PH**, Hu Y, McGregor JG, Jennette JC, Falk RJ, Hogan SL. Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis. *Clin Exp Rheumatol.* 2013; 31(1 Suppl 75):S32-7.
Impact Factor: 2.357
Times Cited: 9
Role: Guarantor of integrity of entire study, Study concept, Study design, Intellectual content, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
43. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med.* 2012; 367(25):2407-18.
Impact Factor: 64.201
Times Cited: 433
Role: Contributor to clinical trial.
44. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, **Nachman PH**, Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. *Arthritis Rheum.* 2012 Oct;64(10):3452-62.
Impact Factor: 8.23
Times Cited: 122
Role: Study concept, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
45. Co-author. KDIGO Clinical Practice Guideline for Glomerulonephritis: *Kidney Int Supplement.* 2012;2(2):139-274.
Impact Factor: 3.357
Times Cited: Not Available. KDIGO guidelines are widely cited and utilized by nephrology community worldwide
Role: Literature review, Manuscript preparation, Manuscript editing, Manuscript review
46. Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, **Nachman PH**, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. *Nephrol Dial Transplant.* 2013 Jan;28(1):137-46.
Impact Factor: 3.938
Times Cited: 13
Role: Contributor to clinical trial, Manuscript review
47. **Nachman PH** and Glasscock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. *Nephrology Self-Assessment Program (NephSAP).* 2012;11:140-217.
Impact Factor: NA
Times Cited: NA

Role: Conducted literature research, Conducted experimental studies, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review

48. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, **Nachman PH**. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. *Clin J Am Soc Nephrol*. 2012 Feb;7(2):240-7.
Impact Factor: 5.355
Times Cited: 43
Role: Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
49. Lionaki S, Derebail V, Hogan SL, Barbour S, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, **Nachman PH***, Reich HN*. Venous Thromboembolism in Patients with Membranous Nephropathy. *Clin J Am Soc Nephrol*. 2012;7(1):43-51. *contributed equally
Impact Factor: 5.355
Times Cited: 78
Role: Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
50. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, **Nachman PH**, Hogan SL, Cattran DC, Reich HN. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. *Kidney Int*. 2012;Jan;81(2):190-5.
Impact Factor: 9.119
Times Cited: 64
Role: Developed Study concept, Developed Study design, Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review
51. Derebail VK, **Nachman PH**, Key NS, Ansede H, Falk RJ, Rosamond WD, Kshirsagar AV. Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. *Kidney Int*. 2011;80(9):992-999.
Impact Factor: 9.119
Times Cited: 10
Role: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review
52. Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, **Nachman PH**, Derebail VK, Bowden DW, Freedman BI. Sick cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. *Kidney Int*. 2011;80(12):1339-1343.
Impact Factor: 9.119
Times Cited: 19
Role: Developed Study concept, Manuscript editing, Manuscript review
53. Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, **Nachman P**, Fervenza FC. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. *Transplantation*. 2011 Jun 27;91:1370-1375.
Impact Factor: 3.726
Times Cited: 38
Role: Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
54. Ataga KI, Brittain JE, Moore D, Jones SK, Hulkower B, Strayhorn D, Adam S, Redding-Lallinger R, **Nachman P**, Orringer EP. Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1. *Eur J Haematol*. 2010 Sep;85(3):257-63.
Impact Factor: 2.378

Times Cited: 29

Role: Developed Study design, Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review

55. **Nachman PH**, Henderson AG. Pathogenesis of lung vasculitis. *Semin Respir Crit Care Med.* 2011; 32:245-53.
Impact Factor: 2.767
Times Cited: 6
Role: Developed concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
56. F.C. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, **Nachman PH**, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC. Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-year study. *Clin J Am Soc Nephrol.* 2010;5:2188-98.
Impact Factor: 5.355
Times Cited: 111
Role: Contributed data, Participated in clinical study, Manuscript preparation, Manuscript editing, Manuscript review
57. **Nachman PH** and Glasscock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program.(NephSAP). 2010;9:123-200.
Impact Factor: NA
Times Cited: NA
Role: Conducted literature research, Conducted experimental studies, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
58. Derebail VK, **Nachman PH**, Key NS, Ansede H, Falk RJ, Kshirsagar AV. High prevalence of sickle cell trait in African Americans with ESRD. *J Am Soc Nephrol.* 2010;21:413-7.
Impact Factor: 9.423
Times Cited: 43
Role: Defined intellectual content, Manuscript preparation, Manuscript editing, Manuscript review
59. Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, Falk RJ, **Nachman PH**. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. *Kidney Int* 2009;76(6):644-51.
Impact Factor: 9.119
Times Cited: 54
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
60. **Nachman PH**. Vasculitis syndromes: which maintenance therapy for ANCA vasculitis? *Nat Rev Nephrol.* 2009 May;5(5):254-6.
Impact Factor: 10.265
Times Cited: 4
Role: Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
61. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, **Nachman PH**. Rituximab therapy for membranous nephropathy: a systematic review. *Clin J Am Soc Nephrol.* 2009 Apr;4(4):734-44.
Impact Factor: 5.355
Times Cited: 69
Role: Manuscript preparation, Manuscript editing, Manuscript review

62. Bunch DO, Silver JS, Majure MC Sullivan P, Alcorta DA, Chin H, Hogan SL, Lindstrom YI, Clarke SH, Falk RJ, **Nachman PH**. Maintenance of Tolerance by Regulation of Anti-myeloperoxidase B Cells. *J Am Soc Nephrol*. 2008;19(9):1763-73.
Impact Factor: 9.423
Times Cited: 5
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
63. Pagnoux C, Chin H, Hogan SL, Falk RJ, Guillevin L, **Nachman PH**. Predictors of Treatment Resistance and Relapse in ANCA Small Vessel Vasculitis: Comparison of Two Independent Cohorts. *Arthritis Rheum*. 2008;58(9):2908-18.
Impact Factor: 7.871
Times Cited: 132
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
64. Lionaki S, Hogan SL, Falk RJ, Joy MS, Jennette CE, **Nachman PH**, Jennette JC. Vasculitis and anti-thyroid medication. *Nephrol Dial Transplant*. 2008;23:1766-8.
Impact Factor: 3.938
Times Cited: 2
Role: Manuscript preparation, Manuscript editing, Manuscript review
65. **Nachman PH** and Glasscock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. *Nephrology Self-Assessment Program (NephSAP)*. 2008;7,131-207.
Impact Factor: NA
Times Cited: NA
Role: Manuscript preparation, Manuscript editing, Manuscript review
66. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, **Nachman P**, Praga M, Yoshikawa N. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome (INS): workshop recommendations. *Kidney International*. 2007;72:1429-47.
Impact Factor: 9.119
Times Cited: 213
Role: Manuscript preparation, Manuscript editing, Manuscript review
67. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, **Nachman PH**. Association of thyroid disease and its treatment with ANCA small vessel vasculitis: A case-control study. *Nephrol Dial Transplant*. 2007;22:3508-15.
Impact Factor: 3.938
Times Cited: 28
Role: Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
68. Culton DA, Nicholas MW, Bunch DO, Zhen QL, Kepler TB, Dooley MA, Mohan C, **Nachman PH**, Clarke SH. Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B cell tolerance loss. *J Clin Immunol* 2007. Jan;27(1):53-68.
Impact Factor: 3.198
Times Cited: 44
Role: Data analysis, Manuscript preparation, Manuscript editing, Manuscript review

69. Hogan SL, Falk RJ, **Nachman PH**, Jennette JC. Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. *Ann Intern Med.* 2006;144(5):377-8; author reply 378-9.
Impact Factor: 17.637
Times Cited: 12
Role: Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
70. Erdbrugger U, Hellmark T, Bunch DO, Alcorta DA, Jennette JC, Falk RJ, **Nachman PH**. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimeras. *Kidney Int.* 2006 May;69(10):1799-805.
Impact Factor:9.119
Times Cited: 26
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
71. **Nachman PH**, Boffa J-J, Falk RJ. Traitement des formes résistantes et récidivantes des vascularites à ANCA. *Actualités Néphrologiques Jean Hamburger. Hôpital Necker.* 2006 ;77-90.
Impact Factor: NA
Role: Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
72. Joy MS, Hogan SL, Jennette JC, Falk RJ, **Nachman PH**. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. *Nephrol Dial Transplant.* 2005 Dec;20(12):2725-32.
Impact Factor: 3.938
Times Cited:
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
73. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, **Nachman PH**. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. *Ann Intern Med.* 2005 Nov 1;143(9):621-31.
Impact Factor: 17.637
Times Cited: 95
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
74. Yang JJ, Pendergraft WF, Alcorta DA, **Nachman PH**, Hogan SL, Thomas RP, Sullivan P, Jennette JC, Falk RJ, Preston GA. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. *J Am Soc Nephrol.* 2004 Aug;15(8):2103-14.
Impact Factor: 9.423
Times Cited: 64
Role: Developed Study concept, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
75. Kshirsagar AV, **Nachman PH**, Falk RJ. Alternative therapies and future intervention for treatment of membranous nephropathy. *Semin Nephrol.* 2003 Jul;23(4):362-72.
Impact Factor: 3.776
Times Cited: 9

- Role: Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
76. Patry YC, **Nachman PH**, Audrain MA, Falk RJ, Meflah K, Esnault VL. Difference in antigenic determinant profiles between human and rat myeloperoxidase. *Clin Exp Immunol*. 2003 Jun;132(3):505-8.
Impact Factor: 3.213
Times Cited: 8
Role: Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
77. **Nachman PH**, Martin J. Developments in the Immunotherapy of Glomerular Disease. *J Pharm Practice*. 2002;(15)472-489.
Impact Factor:
Times Cited: 1
Role: Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
78. Joy MS, Cefalu WT, Hogan SL, **Nachman PH**. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. *Am J Kidney Dis*. 2002 Feb;39(2):297-307.
Impact Factor: 6.452
Times Cited: 110
Role: Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
79. Hogan SL, Satterly KK, Dooley MA, **Nachman PH**, Jennette JC, Falk RF. Silica exposure in ANCA-associated glomerulonephritis and lupus nephritis. *J Am Soc Nephrol*. 2001 Jan;12(1):134-142.
Impact Factor: 9.423
Times Cited: 124
Role: Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
80. Jethwa HS, Clarke SH, Itoh-Lindstrom Y, Falk RJ, Jennette JC, **Nachman PH**. Restriction In V Kappa gene use and antigen selection in anti-myeloperoxidase response in mice. *J Immunol*. 2000 Oct 1;165(7):3890-7.
Impact Factor: 5.185
Times Cited: 6
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
81. Jethwa HS, **Nachman PH**, Falk RJ, Kinjoh K, Jennette JC. False Positive myeloperoxidase binding activity due to DNA/anti-DNA antibody complexes: a source for analytical error in serologic evaluation of antineutrophil cytoplasmic autoantibodies. *Clin Exp Immunol*. 2000 Sept;121(3):544-50.
Impact Factor: 3.213
Times Cited: 23
Role: Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
82. Falk RJ, Hogan SL, **Nachman PH**, Jennette JC. Prognosis and treatment of systemic vasculitis: what is new? *Clin Exp Immunol*. 2000;120(Suppl 1):11-12.
Impact Factor: NA
Times Cited:

Role: Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review

83. Falk RJ, **Nachman PH**, Jennette JC. Immunopathogenesis of small vessel vasculitis. *Clin Exp Immunol.* 2000;120(Suppl 1):21-22.
Impact Factor: NA
Times Cited:
Role: Defined intellectual content, Conducted literature research, Data analysis, Manuscript preparation, Manuscript editing, Manuscript review
84. Falk RJ, **Nachman PH**, Hogan SL, Jennette JC. ANCA Glomerulonephritis and vasculitis: a Chapel Hill perspective. *Sem Nephrol.* 2000;20:233-43.
Impact Factor: 3.776
Times Cited: 90
Role: Defined intellectual content, Conducted literature research, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review
85. Dooley MA, Cosio FG, **Nachman PH**, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. *J Am Soc Nephrol.* 1999;10:833-9.
Impact Factor: 9.423
Times Cited: 204
Role: Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review
86. **Nachman PH**, Segelmark M, Westman K, Hogan SL, Satterly KK, Jennette JC and Falk RJ. Recurrent ANCA-small vessel vasculitis after transplantation: a pooled analysis. *Kidney Int.* 1999;56:1544-50.
Impact Factor: 9.119
Times Cited: 131
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review
87. **Nachman PH**. Joy MS. Glycosylated hemoglobin in the care of patients with diabetes mellitus. *Anna Journal.* 1998;25(2):245-6.
Impact Factor:
Times Cited: 0
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Manuscript preparation, Manuscript editing, Manuscript review
88. **Nachman PH**, Hogan SL, Jennette JC, Falk RJ. Treatment response in patients with ANCA-associated microscopic polyangiitis and glomerulonephritis. *J Am Soc Nephrol.* 1996;6:33-39.
Impact Factor: 9.423
Times Cited: 247
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review
89. Hogan SL, **Nachman PH**, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with ANCA-associated microscopic polyangiitis glomerulonephritis. *J Am Soc Nephrol.* 1996;6:23-32.
Impact Factor: 9.423
Times Cited: 304

Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review

90. **Nachman PH**, Reisner HM, Yang JJ, Jennette JC, Falk RJ: Shared idiotype among patients with myeloperoxidase-ANCA-associated glomerulonephritis and vasculitis. *Lab Invest.* 1996;74,519-27. Impact Factor: 4.401
Times Cited: 11
Role: Guarantor of integrity of entire study, Developed Study concept, Developed Study design, Defined intellectual content, Conducted literature research, Conducted experimental studies, Data acquisition, Manuscript preparation, Manuscript editing, Manuscript review

Published Abstracts

1. Singh HK, Hogan SL, Poulton CJ, Hu, Y, **Nachman PH**. Characteristics associated with repeat native renal biopsy in lupus nephritis. *J Am Soc Nephrol* 29:2018
2. Murphy SL, Powell J, Dorough A, Mottl AK, Reeve BB, **Nachman PH**. Symptoms and health-related quality of life (HRQOL) in primary membranous nephropathy. *J Am Soc Nephrol* 29:2018
3. Murphy SL, Gbadegesin RA, Herreshoff EG, Canetta PA, **Nachman PH**, Reeve BB, Selewski DT, Sethna CB, Wang CS, Bartosh SM, Gipson DS, Mahan JD, Tuttle KR, Troost JP, Srivastava T, Kogon A, Cai Y, Davis TK, Fernandez HE, Fornoni A, Changes in Patient-Reported Outcomes and Glomerular Disease Activity: CureGN *J Am Soc Nephrol* 29:2018
4. Glenn DA, Mottl AK, Hogan SL, **Nachman PH**, Falk RJ, Henderson CD, Hu Y, Zinsser D, O'Shaughnessy MM., Greenbaum LA., Zee J, Bomback AS., Gibson KL. Infectious Complications in Patients with Glomerular Disease: An Analysis of the Cure Glomerulonephropathy (CureGN) Study. *J Am Soc Nephrol* 29:2018
5. Bruchfeld A, **Nachman PH**, Parikh S, Lafayette R, Potarca A, Diehl J, Lohr L, Miao S, Bekker P, Schall TJ, Hillson JL. C5a receptor inhibitor Avacopan in IgA Nephropathy – a pilot study. *Kidney Dis* 2018;4:140-141
6. Bunch DO, Deng J, McInnis EA, Bekker P, Hillson JL, Schall TJ, Jennette JC, **Nachman P** for the CLEAR Study Group. Effect of a selective C5aR antagonist, Avacopan (CCX168), on plasma complement levels in ANCA associated vasculitis (AAV). *Ann Rheum Dis* 2018; 77:74-75. DOI: 10.1136/annrheumdis-2018-eular.6032.
7. Lardinois O, Henderson CD, Poulton CJ, **Nachman PH**. O-Glycan Profiling of High Molecular Weight Forms of IgA1 in Archival Plasma Samples from IgAN Patients and Controls *J Am Soc Nephrol* 28:2017
8. Mendoza CE, Brant EJ, Mcdermott ML, Froment AB, Hu Y, Hogan SL, Jennette JC, Falk RJ, **Nachman PH**, Derebail VK, Bunch DO. Microparticle Tissue Factor Activity Dominates Venous Thromboembolism Signature in ANCA Vasculitis. *J Am Soc Nephrol* 28:2017
9. Canetta PA, Bartosh SM, Cai Y, Fernandez HE, Fornoni A, Gbadegesin RA, Herreshoff EG, Kogon A, Mahan JD, Mahoney SL, **Nachman PH**, Selewski DT, Srivastava T, Tuttle KR, Wang CS, Troost JP, Gipson DS. Health Related Quality of Life (HRQOL) in Primary Glomerular Disease: The Initial CureGN Experience. *J Am Soc Nephrol* 28:2017
10. Jeremy J. Sorkin,4 **Patrick H. Nachman**, Vimal K. Derebail,2 Roshni Radhakrishna,4 Volker Nickeleit,1 Alexei V. Mikhailov.3 Hello, Goodbye Proteinuria. *J Am Soc Nephrol* 28:2017

11. Selewski DT, Ambruzs JM, Appel GB, Bombback AS, Cattran DC, Fava M, Gillespie BW, Helmuth M, Hogan JJ, Julian BA, Lafayette RA, **Nachman PH**, Nast CC, Novak J, O'Shaughnessy MM, Palmer M, Reich HN, Rizk D, Robinson BM, Sanghani NS, Sexton M, Sperati J, Zee J, Kiryluk K. The Cure Glomerulonephropathy (CureGN) IgA Nephropathy and IgA Vasculitis Cohort J Am Soc Nephrol 28: 2017
12. Youngho Kim, Caroline J. Poulton, Yichun Hu, Susan L.Hogan, Amy K. Mottl, Ronald J. Falk, J. Charles Jennette, **Patrick H. Nachman** Diabetic and Non-Diabetic Kidney Disease in Patients with Diabetes Mellitus (DM). J Am Soc Nephrol 28: 2017
13. Roshni Radhakrishna, Manish K. Saha,² Volker Nickeleit,¹ **Patrick H. Nachman** IgA Nephropathy: A Diagnostic Dilemma J Am Soc Nephrol 28: 2017
14. Troost JP, Tractman H, Spino C, Komers R, Tuller SE, **Nachman PH**, Kretzler M, Gipson DS. A Clinical Outcome Assessment of Proteinuria in Patients with Focal Segmental Glomerulosclerosis. J Am Soc Nephrol 27: 2016
15. Lardinois O, Deterding L, Poulton CJ, Henderson C, **Nachman PH**, Jennette JC, Falk RJ. Atypical Glycosylation of the Constant and Variable Domains of Immunoglobulin G from Patients with ANCA- Associated Systemic Vasculitides: Relation to Disease Activity. J Am Soc Nephrol 27: 2016
16. Wu E, Boyer SB, McInnis EA, Hu Y, Hogan SL, Poulton CJ, Hu P, Xiao H, Falk RJ, Jennette JC, **Nachman PH**, Bunch DO. Measuring Complement Activation in ANCA-Associated Vasculitis. J Am Soc Nephrol 27: 2016
17. Boyer SB, Wu E, McInnis EA, Aybar L, Mendoza CE. Hu Y, Hogan SL, Falk RJ, **Nachman PH**, Jennette JC, Bunch DO. Circulating Complement Activation Products in MPO and PR3 ANCA Vasculitis. J Am Soc Nephrol 27: 2016
18. Boyer SB, McInnis EA, Nickeleit V, **Nachman PH**. Crescentine and Necrotizing Glomerulonephritis with IgA deposition and Circulating IgG and IgA ANCA. J Am Soc Nephrol 27: 2016
19. Brant EJ, Mendoza CE, Mcdermott ML, Hu Y, Hogan SL, Jennette JC, Falk RJ, **Nachman PH**, Derebail VK, Bunch DO. Elevated Microparticle Tissue Factor Activity Predicts Venous Thromboembolism in ANCA Vasculitis. J Am Soc Nephrol 27: 2016
20. Derebail VK, Brant EJ, Mendoza CE, Hogan SL, Key NS, Mackman N, Reich HN, **Nachman PH**, Bunch DO. Oxidized Low Density Lipoprotein and Microparticle Tissue Factor Activity in the Nephrotic Syndrome. J Am Soc Nephrol 27: 2016
21. **Nachman PH**, Hu Y, Poulton CJ, Pendergraft WF, Falk RJ, Hogan SL. Risk Factors of Treatment-Related Diabetes Mellitus in ANCA Vasculitis. J Am Soc Nephrol 27: 2016
22. Laurin LP, Foster BJ, Gasim A. Poulton CJ, Jennette JC,² Falk RJ, **Nachman PH**. The Role of Calcineurin Inhibitors in Early Treatment of Primary FSGS. J Am Soc Nephrol 26: 2015
23. Lee T, Derebail VK, Cattran DC, Falk RJ, Reich HN, **Nachman PH**. In Primary Membranous Nephropathy, Relapse After Partial Remission Is Predicted by Serum Albumin Level. J Am Soc Nephrol 26: 2015

24. Lee T, Derebail VK, Cattran DC, Falk RJ, Reich HN, **Nachman PH**. Clinical Significance and Risk Factor of Relapse in Proteinuria in Primary Membranous Nephropathy. *J Am Soc Nephrol* 26: 2015
25. Katsanos SL, **Nachman PH**, McGregor JAG, Nickleit V. Collapsing and NOS Focal Segmental Glomerulosclerosis (FSGS): Progression Along a Spectrum or Different Diseases? *J Am Soc Nephrol* 26: 2015
26. Swain KA, Liu H, Nickleit V, **Nachman PH**. A Curious SLE Tangled Case: Systemic Lupus Erythematosus as the Unifying Diagnosis for Fibrillary Glomerulopathy and Toxic Epidermal Necrolysis. *J Am Soc Nephrol* 26: 2015
27. Brant EJ, Mendoza CE, Hu Y, Hogan SL, Falk RJ, **Nachman PH**, Derebail VK, Bunch DO. Venous Thromboembolism in ANCA Vasculitis Is Associated with Elevated Microparticle Tissue Factor Activity. *J Am Soc Nephrol* 26: 2015
28. Troost JP, Gipson DS, Reeve BB, **Nachman PH**, Gbadegesin RA, Wang J, Modersitzki F, Massengill SF, Mahan JD, Trachtman H, Selewski DT. Latent Profiles of Patient Reported Outcomes in Nephrotic Syndrome Patients. *J Am Soc Nephrol* 26: 2015
29. Laurin LP, Foster BJ, Gasim A, Poulton CJ, Jennette JC, Falk RJ, **Nachman PH**. Factors Influencing Initiation and Choice of Immunosuppressive Therapy in Primary FSGS. *J Am Soc Nephrol* 26: 2015
30. Lee T, Derebail VK, Kshirsagar AV, Poulton CJ, Hogan SL, Lionaki S, Falk RJ, Reich HN, **Nachman PH**. The Risk of Cardiovascular events (CVE) is Greater in Membranous Nephropathy (MN) Than Focal Segmental Glomerulosclerosis (FSGS). *J Am Soc Nephrol* 25: 2014
31. Brown LC, Free ME, Chang EH, Laurin LP, Falk RJ, **Nachman PH**, Pendergraft WF. Rituximab-Induced B Cell Depletion for Treatment of Refractory Minimal Change Glomerulopathy. *J Am Soc Nephrol* 25: 2014.
32. Troost J, Selewski DT, **Nachman PH**, Massengill SF, Herreshoff EG, Lienczewski CC, Klim AM, Gipson DS. Patient Reported Outcomes in Children and Adults with Nephrotic Syndrome. *J Am Soc Nephrol* 25: 2014.
33. Basta B, **Nachman PH**, Singh HK, Pendergraft WF, Hladik GA, Payan Schober F, Grossman SH. IgA Nephropathy (IgAN) and Pregnancy: The Challenge of Distinguishing between Preeclampsia and Progressive Glomerulonephritis (GN). *J Am Soc Nephrol* 25: 2014
34. McGregor JAG, Poulton CJ, Kidd JM, Katsanos SL, Goetz LR, Hu Y, **Nachman PH**, Falk RJ, Hogan SL. Timing and Types of Infections After Diagnosis and Antineutrophil Cytoplasmic Antibody Associated Vasculitis. *J Am Soc Nephrol* 25: 2014
35. Jain K, Gupta A, Swain KA, **Nachman PH**, True KA. Recurrent Immunotactoid Glomerulopathy in a Transplanted Kidney. *J Am Soc Nephrol* 25: 2014
36. Roth A, Ooi J, Hess J, Van Timmeren M, Berg E, Poulton C, McGregor J, Burkart M, Hogan S, Hu Y, Winnik W, **Nachman P**, Stegeman C, Niles J, Heeringa P, Free M, Kitching R, Holdsworth S, Jennette C, Preston G, Falk R. ANCA epitope specificity determines

- pathogenicity, detectability and clinical predictive value. *Presse Med.* 2013;42;664.
37. Lee T, Gasim A, McGregor JAG, Derebail VK, Poulton CJ, Lionaki S, Hogan SL, Jennette JC, Falk RJ, **Nachman PH**. Prognosis of patients with ANCA-associated glomerulonephritis (GN) presenting with severe renal failure. *Presse Med.* 2013;42;671.
 38. Bunch D, McGregor JAG, Aybar L, Studhill E, Hu Y, Hogan S, Colby K, Poulton C, Mendoza C, Schmitz J, Falk R, **Nachman P**. Low %CD5 B cells in patients with ANCA vasculitis portends a shorter time to relapse after rituximab. *Presse Med.* 2013;42;754.
 39. McGregor J, Negrete-Lopez R, Poulton C, Kidd J, Weaver S, Goetz L, Hu Y, **Nachman P**, Falk R, Hogan S. Infectious complications related to treatment in an inception cohort of antineutrophil cytoplasmic antibody- associated vasculitis. *Presse Med.* 2013;42;767.
 40. Studhill ME, McGregor J, Poulton C, Hu Y, **Nachman P**, Falk R, Hogan S. Time to remission and relapse following rituximab in an inception cohort of antineutrophil cytoplasmic vasculitis. *Presse Med.* 2013;42;774.
 41. Froment AB, Newton VM, Hogan SL, Hu Y, Belger A, **Nachman PH**, [FR-PO268] Detailed analysis of cognitive function in patients on hemodialysis (HD). *J Am Soc Nephrol.* 2012, 23.
 42. Froment AB, Newton VM, Hogan SL, Hu Y, Belger A, **Nachman PH**, [FR-PO269] Longitudinal study of change in cognitive function in patients on hemodialysis (HD). *J Am Soc Nephrol.* 2012,23.
 43. Aleeza J. Roth, Jacob Hess, Mirjan M. Van timmeren, PhD, Elisabeth Berg, Caroline J. Poulton, Madelyn Burkart, Susan L. Hogan, PhD, Yichun Hu, **Patrick H. Nachman**, MD, FASN, Coen A. Stegeman, MD, Peter Heeringa, PhD, J. Charles Jennette, MD, Gloria A. Preston, PhD, Ronald J. Falk [FR-OR135]. ANCA epitope specificity determines pathogenicity. *J Am Soc Nephrol.* 2012, 23.
 44. Taewoo Lee, MD, Andrea K. Biddle, PhD, Sean Barbour, MD, Sophia Lionaki, MD, Yichun Hu, Vimal K. Derebail, MD, Michelle A. Hladunewich, MD, FASN, Caroline J. Poulton, Shannon L. Mahoney, Susan L. Hogan, PhD, Shannon L. Mahoney, Ronald J. Falk, MD, FASN, Daniel C. Cattran, MD, Heather N. Reich, MD, PhD, **Patrick H. Nachman** [FR-OR127] Prophylactic anticoagulation in membranous nephropathy: a decision analysis. *J Am Soc Nephrol.* 2012,23.
 45. Donna O. Bunch, PhD, JulieAnne G. McGregor, MD, Lydia Aybar, Kerry R. Colby, MD, Yichun Hu, Susan L. Hogan, PhD, Caroline J. Poulton, Elisabeth Berg, John Schmitz, Ronald J. Falk, MD, FASN, **Patrick H. Nachman**, [FR-OR137] Reduced CD5+ B cells in active anti-neutrophil cytoplasmic autoantibody vasculitis and relapse after rituximab. *J Am Soc Nephrol.* 2012,23.
 46. Duvuru Geetha, MD, FASN, Caroline J. Poulton, Yichun Hu, Philip Seo, MD, JulieAnne G. McGregor, MD, **Patrick H. Nachman** [SA-PO316]. Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. *J Am Soc Nephrol.* 2012,23.
 47. Taewoo Lee, MD, Vimal K. Derebail, MD, Caroline J. Poulton, Sophia Lionaki, MD, JulieAnne G. McGregor, MD, Susan L. Hogan, PhD, J. Charles Jennette, MD, Ronald J. Falk, MD, FASN, **Patrick H. Nachman** [SA-PO318]. Prognosis of ANCA-associated glomerulonephritis (ANCA-

- GN) requiring dialysis at presentation. *J Am Soc Nephrol.* 2012,23.
48. Roberto Negrete, MD, JulieAnne G. McGregor, MD, Caroline J. Poulton, Yichun Hu, **Patrick H. Nachman**, MD, FASN, Ronald J. Falk, MD, FASN, Susan L. Hogan [SA-PO328]. Infection and mortality in anti- neutrophil cytoplasmic antibody-associated vasculitis. *J Am Soc Nephrol.* 2012,23.
 49. Louis-Philippe Laurin, MD, JulieAnne G. McGregor, MD, Vimal K. Derebail, MD, Susan L. Hogan, PhD, Caroline J. Poulton, Adil MH Gasim, MD, J. Charles Jennette, MD, Ronald J. Falk, MD, FASN, **Patrick H. Nachman** [SA-PO380]. Role of immunosuppressive therapy in renal survival in collapsing focal segmental glomerulosclerosis (FSGS) *J Am Soc Nephrol.* 2012,23.
 50. Freedman BI, Hicks PJ, Langefeld CD, Lingyi L, Bleyer AJ, Divers J, **Nachman PH**, Derebail VK, Bowden DW. Sickle cell trait is not associated with ESRD susceptibility in African Americans. *J Am Soc Nephrol.* 2011,22.
 51. Irazabal MV, Eirin A, Lieske JC, Beck LH, Dillon JJ, **Nachman PH**, Sethi S, Erickson SB, Cattran DC, Fervenza FC. Urinary biomarkers as predictors of response to rituximab in patients with membranous nephropathy. *J Am Soc Nephrol.* 2011,22.
 52. Lionaki S, Barbour S, Hu Y, Hogan SL, Jennette CE, Falk RJ, Cattran DC, **Nachman PH**, Reich HN. The occurrence of cancer in patients with membranous nephropathy. *J Am Soc Nephrol.* 2011,22.
 53. Mahoney SL, Derebail VK, Biddle A, Hu Y, Hladunewich MA, Falk RJ, Cattran DC, Reich HN, **Nachman PH**. Factors influencing treatment choice in idiopathic membranous nephropathy (IMN). *J Am Soc Nephrol.* 2011,22.
 54. McGregor JAG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Corticosteroid therapy beyond 6 months does not decrease relapse in ANCA disease. *J Am Soc Nephrol.* 2010,21.
 55. Lionaki S, Derebail V, Hogan SL, Hladunewich M, Barbour S, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, **Nachman PH**, Reich HN. Hypoalbuminemia is a risk factor of venous thromboembolism in membranous nephropathy (MN). *J Am Soc Nephrol.* 2010,21.
 56. Geetha D, Eirin A, True KA, Irazabal-Mira MV, Specks U, Seo P, **Nachman PH**, Fervenza FC. A multicenter Experience of Kidney Transplantation in ANCA-associated vasculitis (AAV) in the era of modern immunosuppression. *J Am Soc Nephrol.* 2010,21.
 57. Fervenza FC, Abraham R, Erickson SB, Irazabal-Mira MV, Eirin A, Specks U, **Nachman PH**, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LTJ, Cattran DC. Efficacy, durability and immunological analyses following rituximab therapy in idiopathic membranous nephropathy: a 2-year study. *J Am Soc Nephrol.* 2010,21.
 58. Lionaki S, Hogan SL, Hu Y, Jennette CE, **Nachman PH**, Jennette JC, Falk RJ Current Classification Systems for ANCA-SVV: Differences in ANCA specificity and predictive value for outcomes. *J Am Soc Nephrol.* 2009;20.
 59. Fervenza FC, Erickson SB, **Nachman PH**, Dillon JJ, Leung N, Hogan MC, Hickson LT, Qazi Q, Bergstralh EJ, Irazabal MV, Erin A, Cattran DC. Rituximab (RTX) in the treatment of idiopathic membranous nephropathy (IMN). *J Am Soc Nephrol.* 2009;20.

60. Fervenza FC, Erickson SB, **Nachman PH**, Dillon JJ, Leung N, Hogan MC, Hickson LT, Anand B, Visich J, Irazabal MV, Eirin A, Cattran DC. Pharmacokinetics (PK) of rituximab in idiopathic membranous nephropathy (IMN). *J Am Soc Nephrol.* 2009;20.
61. Irazabal MV, Eirin A, Lieske J, Borland TM, Erickson SB, Dillon JJ, **Nachman PH**, Cattran DC, Fervenza FC. Fractional excretion of high and low molecular weight proteins correlates with response to rituximab (RTX) therapy in patients with idiopathic membranous nephropathy (MN): A prospective study. *J Am Soc Nephrol.* 2009;20.
62. Derebail VK, **Nachman PH**, Key N, Falk RJ, Kshirsagar AV. High prevalence of sickle cell trait in African- Americans with end-stage renal disease. *J Am Soc Nephrol.* 2009;20.
63. Eirin A, Irazabal MV, Abraham RS, Erickson SB, **Nachman PH**, Lieske JC, Leung N, Dillon JJ, Cattran DC, Fervenza FC. Quantification of B cell and T cell subsets do not predict response to rituximab therapy in patients with idiopathic membranous nephropathy: a prospective study. *J Am Soc Nephrol.* 2009;20.
64. Lionaki S, Hogan S, Hu Y, Jennette CE, **Nachman PH**, Jennette JC, Falk RJ. Antigen specificity of ANCA correlates with both clinical expression and prognosis in ANCA small vessel vasculitis (SVV). *J Am Soc Nephrol.* 2009;20.
65. Valdes RA, Key NS, Schmitz JL, **Nachman P**, Bunch D, Burkart ME, Jennette JC, Falk RJ, Detwiler R. Class II HLA expression in HUVEC derived microparticles during apoptosis and cellular activation. *APMIS* 2009;117:131.
66. Lionaki S, Hogan SL, Hu Y, Jennette CE, **Nachman PH**, Jennette JC, Falk RJ. Current classification systems for ANCA-SVV: differences in ANCA specificity and predictive value for outcomes. *APMIS* 2009;117:146.
67. Lionaki S, Hogan SL, Hu Y, Jennette CE, Senior B, **Nachman PH**, Jennette JC, Falk RJ. Specificity of ANCA portrays both clinical expression and prognosis in ANCA vasculitis. *APMIS* 2009;117:152.
68. Fervenza FC, Erickson SB, Dillon JJ, **Nachman P**, Hogan MC, Haugen EN, Leung N, Wochos DN, Cattran DC. Angiotensin II (Ang II) blockade is ineffective in reducing proteinuria in patients with severe membranous nephropathy (MN). *J Am Soc Nephrol.* 2008;19:559A.
69. S. L. Hogan, S. Lionaki, C. E. Jennette, Y. Hu, J. C. Jennette, R. J. Falk, **P. H. Nachman**. The association of perinatal and family history of autoimmune disease in development of membranous nephropathy (MN): a case-control study. *J Am Soc Nephrol.* 2008;19:970A.
70. D. O. Bunch, N. B. Khandooobhai, M. A. Amamoo, S. L. Hogan, J. B. Hamra, J. K. Piscitello, R. J. Falk, **P. H. Nachman**. Rituximab normalizes some B cell phenotypes. *J Am Soc Nephrol.* 2008;19:661A.
71. S. Lionaki, S. L. Hogan, C. E. Jennette, Y. Hu, J. B. Hamra, J. C. Jennette, R. J. Falk, **P. H. Nachman**. Clinical course of ANCA small vessel vasculitis (SVV) on chronic dialysis. *J Am Soc Nephrol.* 2008;19:783A.
72. S. L. Hogan, D. S. Gipson, M. Ferris, C. E. Jennette, Y. Hu, **P. H. Nachman**, J. C. Jennette, R. J. Falk. The life course of body weight and development of focal segmental glomerulosclerosis (FSGS): a case-control study. *J Am Soc Nephrol.* 2008;19:328A.

73. Susan L. Hogan, Sofia Lionaki, Caroline E. Jennette, Yichun Hu, J. Charles Jennette, Ronald J. Falk, **Patrick H. Nachman**, Abhijit Kshirsagar. The role of infection in the development of membranous nephropathy (MN): A case-control study. *J Am Soc Nephrol.* 2008;19:328A.
74. S. L. Hogan, S. Vupputuri, S. Lionaki, C. E. Jennette, Y. Hu, J. C. Jennette, R. J. Falk, **P. H. Nachman**. Association of heavy metals with the development of membranous nephropathy (MN): a case-control study. *J Am Soc Nephrol.* 2008;19:329A.
75. S. Lionaki, S. L Hogan, J. C. Jennette, C. E. Jennette, K. Hendrickson, Y. Hu, R. J. Falk, **P. H. Nachman**. Epidemiology of malignancy in patients with membranous nephropathy (MN). *J Am Soc Nephrol.* 2008;19:329A.
76. Bunch DO, Khandoobhai NB, Amamoo A, Chin H, Hogan SL, Hamra JB, Falk RJ, **Nachman PH**. Alterations in B cell phenotypes in patients with ANCA vasculitis: correlation with disease activity. *J Am Soc Nephrol.* 2007;18:192A.
77. Lionaki S, Chin H, Hogan SL, Senior BA, Jennette CE, Cooper JD, **Nachman PH**, Jennette JC, Falk RJ. Comparison of ear, nose and throat (ENT) manifestations in ANCA-small vessel vasculitis (ANCA-SVV): Wegener's granulomatosis (WG) versus microscopic polyangiitis (MPA). *J Am Soc Nephrol.* 2007;18:784A.
78. R A Valdes, N S Key, J L Schmitz, G Kemeny, **P Nachman**, D Alcorta, K True, D Bunch, M E Burkart, J C Jennette, R J Falk and R Detwiler. A novel approach to measuring microparticles (MPs) using HLA Class I (HLA-1). *J Am Soc Nephrol.* 2007;18:226A.
79. Xiao H, Zhang B, Schreiber A, WenSui, Erdbrugger U, Bunch DO, Hellmark T, **Nachman PH**, Falk RJ, Jennette JC. Recombinant mouse myeloperoxidase (MPO) induces necrotizing and crescentic glomerulonephritis in mice. *J Am Soc Nephrol.* 2007;18:190A.
80. Cooper JD, Hogan SL, Chin H, Falk RJ, **Nachman PH**. Mycophenolate mofetil (MMF) + cyclosporine-A (CyA) therapy for active ANCA vasculitis. *J Am Soc Nephrol.* 2006;17:574A.
81. Gibson KL, Chin H, Nester C, Massengill S, Hogan SL, **Nachman P**, Wong C, Falk RJ, Thomas DB, Gipson DB. Treatment and survival outcomes of ANCA vasculitis in children versus adults. *J Am Soc Nephrol.* 2006;17:732A.
82. Chin H, Pagnoux C, Hogan SL, Guillevin L, Falk RJ, **Nachman PH**. Predictors of relapse in ANCA vasculitis: comparison of 2 independent cohorts. *J Am Soc Nephrol.* 2006;17:802A.
83. Bunch DO, Khandoobhai NB, Clarke SH, Falk RJ, **Nachman PH**. Regulators of B cell receptor signaling are altered in patients with ANCA vasculitis. *J Am Soc Nephrol.* 2006;17:353A.
84. Bunch DO, Khandoobhai N, Chin H, Hogan SL, Clarke SH, Falk RJ, **Nachman PH**. B cell subpopulations are altered in patients with active ANCA vasculitis. *J Am Soc Nephrol.* 2005;16:778A.
85. Hogan SL, Joy MS, Chin H, Jennette JC, Falk RJ, **Nachman PH**. Strong association of thyroid disease and its treatment with ANCA-SVV. *J Am Soc Nephrol.* 2005;16:555A.
86. Jennette CE, Chin H, Falk RJ, **Nachman PH**, Hogan SL. Delay of diagnosis in patients with

- ANCA small vessel vasculitis. *J Am Soc Nephrol.* 2005;16:555A.
87. Radhakrishnan J, Weiss S, **Nachman P**, Adler S, Appel G. Rituximab (RMB) in glomerular disease (GD). *J Am Soc Nephrol.* 2005;16:528A.
 88. Erdbruegger U, Hellmark T, Alcorta DA, Bunch DO, **Nachman PH**. Most myeloperoxidase (MPO)-ANCA show stable binding to a restricted number of epitopes. *J Am Soc Nephrol.* 2004;15:680A.
 89. Bunch DO, Silver J, **Nachman PH**. Anti-MPO B cells of anti-MPO light chain transgenic mice are regulated by deletion and diversion to marginal zone B1 B cells. *J Am Soc Nephrol.* 2004;15:680A.
 90. Appel G, **Nachman P**, Hogan S, Radhakrishnan J, Old C, Hebert L, Fervenza F, Kumor K, Petro B, Lan L, Hardman J. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (IMN): preliminary baseline and pharmacokinetic (PK)/pharmacodynamic (PD) data. *J Am Soc Nephrol.* 2002;13:668A.
 91. Erdbruegger U, Hellmark T, Majure MCM, Bunch DO, **Nachman PH**. Comparative binding of anti- myeloperoxidase (MPO) antibodies to human and mouse MPO. *J Am Soc Nephrol.* 2002;13:174A.
 92. Patry Y, **Nachman PH**, Audrain MAP, Muller J-Y, Falk RJ, Esnault VLM. Difference in antigenic determinant profiles between human and rat myeloperoxidase. *J Am Soc Nephrol.* 2001;12:638A.
 93. Hellmark T, Majure MC, Jethwa HS, Clarke SH, Falk RJ, **Nachman PH**. Variable region gene use in human anti-myeloperoxidase antibodies. *J Am Soc Nephrol.* 2001;12:632A.
 94. Itoh-Lindstrom Y, Taylor TV, Clarke SH, Jennette JC, Falk RJ, **Nachman PH**. Generation of anti-MPO B cells in V κ 1C transgenic mice. *J Am Soc Nephrol.* 2000;11:476A.
 95. Taylor TV, Itoh-Lindstrom Y, Clarke SH, Jennette JC, Falk RJ, **Nachman PH**. Anti-Myeloperoxidase (MPO)-derived light chain confers antibody specificity to MPO. *J Am Soc Nephrol.* 2000;11:483A.
 96. **Nachman PH**, Joy MS, Hogan SL, Jennette JC, Falk RJ. Preliminary results of a pilot study on the use of mycophenolate mofetil (MMF) in relapsing ANCA small vessel vasculitis (ANCA-SVV). *J Am Soc Nephrol.* 2000;11:158A.
 97. Holder S, Hogan SL, **Nachman PH**, Jennette JC, Falk RJ. Response to corticosteroids (CS) and ACE inhibitors/ACE receptor antagonists (ACEi/ARB) in a contemporary cohort of patients with focal segmental glomerulosclerosis (FSGS). *J Am Soc Nephrol.* 2000;11:99A.
 98. Hogan SL, ten Holder S, **Nachman PH**, Wilkman AS, Jennette JC, Falk RJ. Predictors of outcome in a contemporary cohort of patients with focal segmental glomerulosclerosis (FSGS). *J Am Soc Nephrol.* 2000;11:87A.
 99. Itoh-Lindstrom Y, Taylor TV, Clarke SH, Jennette JC, Falk RJ, **Nachman PH**. V κ 1C light-chain transgenic mice—a mouse model for anti-MPO B cell regulation. *Clin Exp Immunol.* 2000,120(Suppl 1):45.
 100. **Nachman PH**, Joy MS, Hogan SL, Jennette JC, Falk RJ. Mycophenolate Mofetil (MMF):

- Preliminary results of a feasibility trial in relapsing ANCA small vessel vasculitis. *Clin Exp Immunol.* 2000, 120(Suppl 1):72.
101. Hogan SL, **Nachman PH**, Jennette JC, and Falk RJ. The role of ANCA pattern and diagnosis in clinical presentation and outcomes in ANCA-associated small vessel vasculitis (ANCA-SVV). *J Am Soc Nephrol.* 1999;10:104A.
 102. Satterly KK, Hogan SL, **Nachman PH**, Dooley MA, Jennette JC, Falk RJ. ANCA-associated diseases with renal involvement but not lupus nephritis are associated with silica exposure. *Clin Exp Immunol.* 1998, 112(Suppl 1):25.
 103. Kopp JB, Vlahov D, Macalino G, Briggs WA, Korbet SM, Berns JS, Kimmel PL, Welch TR, Smith MC, Schelling JR, Simon E, **Nachman PH**, Hutchison F, Rao TKS, Ripley E, Wachter L, Nelson G, Winkler C.
 104. Joy MS, Cefalu WT, Hogan SL, Kirby R and **Nachman PH**. Assessment of measures of long-term glycemic control in diabetic patients with ESRD. *J Am Soc Nephrol.* 1998;9:117A.
 105. **Nachman PH**, Hogan SL, Satterly KK, Jennette JC, Falk RJ. Recurrent ANCA-small vessel vasculitis (SVV) and glomerulonephritis (GN) after transplantation: a pooled analysis. *J Am Soc Nephrol.* 1997;8:696A.
 106. **Nachman PH**, Dooley MA, Hogan SL, Aiello JR, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). Mycophenolate mofetil therapy in patients with cyclophosphamide (CyP) resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN). *J Am Soc Nephrol.* 1997;8:94A.
 107. **Nachman PH**, Hogan SL, Dooley MA, Satterly KK, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). Remission and relapse in ANCA small vessel vasculitis (SVV) by ANCA antigen specificity and by disease category. *J Am Soc Nephrol.* 1997;8:94A.
 108. Hogan SL, **Nachman PH**, Dooley MA, Satterly KK, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). ANCA antigen specificity in 192 patients with glomerulonephritis (GN), microscopic polyangiitis (MPA), or Wegener's granulomatosis (WG). *J Am Soc Nephrol.* *J Am Soc Nephrol* 1997;8:87A.
 109. Morris CR, Hogan SL, **Nachman PH**: Meta-analysis of randomized trials using mycophenolate mofetil (MMF) in renal transplantation. *J Am Soc Nephrol.* 1997;8:695A.
 110. Jethwa HS, Clarke S, Taylor JG, Jennette JC, Falk RJ, **Nachman PH**. Variable region gene selection in murine anti-myeloperoxidase (MPO) autoantibodies. *J Am Soc Nephrol.* 1997;8:457A.
 111. **Nachman PH**, Hogan SL, Dooley MA, Satterly KK, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). Remission, relapse and side effects in patients with ANCA-small vessel vasculitis (SVV) treated with intravenous (IV) versus oral cyclophosphamide (CyP). *J Am Soc Nephrol.* 1997;8:94A.
 112. **Nachman PH**, Clarke SH, Kinjoh K, Taylor J, Jennette JC, Falk RJ: Cross-reactivity of murine monoclonal auto-antibodies (Mab) to DNA and myeloperoxidase (MPO). *J Am Soc Nephrol.* 1995;3,845.

113. Kinjoh K, Good RA, Taylor J, **Nachman PH**, Falk RJ, Jennette JC: Hybribomas from SCG/Kj mice produce P-ANCA with specificity for myeloperoxidase (MPO) and induce proteinuria in nude mice. *Clin Exp Immunol.* 1995;101,37.
114. **Nachman PH**, Royal MO, Kinjoh K, Reisner HM, Jennette JC, Falk RJ: Murine monoclonal anti-MPO autoantibody reacts to an epitope commonly recognized by human ANCA. *Clin Exp Immunol.* 1995;101,38.
115. **Nachman PH**, Hogan SL, Jennette JC, Falk RJ: Treatment response in ANCA-associated microscopic polyangiitis (MPA) and necrotizing and crescentic glomerulonephritis. *Clin Exp Immunol.* 1995;101,44.
116. **Nachman PH**, Reisner HM, Jennette JC, Falk RJ: A study of shared idiotypy among patients with myeloperoxidase-ANCA (MPO-ANCA) associated disease. *J Am Soc Nephrol.* 1994;5,839.
117. **Nachman PH**, Hogan SL, Jennette JC, Falk RJ: A study of relapse in patients with anti-neutrophil cytoplasmic autoantibody ANCA) associated vasculitis. *J Am Soc Nephrol.* 1994;5,838.
118. **Nachman PH**, Reisner HM, Jennette JC, Falk RJ: The clonality of myeloperoxidase (MPO)-ANCA by isoelectro-focusing. *J Am Soc Nephrol.* 1993;4,622.
119. **Nachman PH**, Terrell RS, Jennette JC, Falk RJ: Naturally occurring anti-myeloperoxidase (MPO) antibodies. *J Am Soc Nephrol.* 1993;4,622.

Educational Videos-Physician Education Material

Online Web-based tool

Principal investigator and senior authors. I was involved at all level of development of the tool except for the coding.

Decision Aid for Prophylactic Anticoagulation in Patients with Membranous Nephropathy:

<https://www.med.unc.edu/gntools/>

Chapters in Books

1. Glassock RJ and **Nachman PH**. Renal-Limited Vasculitis. In: Treatment of Primary Glomerulonephritis. Edited by Ponticelli C and Glassock RJ. Third edition. *In Press*
2. **Nachman PH**, Boyer SB, Jennette JC, Falk RJ. Kidney Involvement in Systemic Vasculitis. In: National Kidney Foundation's Primer on Kidney Diseases. 7th edition. Edited by Scott J Gilbert and Daniel E. Weiner. Elsevier. 2017
3. Murphy S, **Nachman PH**. ANCA-Associated Vasculitis. In: Glomerulonephritis. Edited by Howard Trachtman, Leal C. Herlitz, Edgar V. Lerma and Jonathan J. Hogan. Springer 2019

4. McGregor JA, **Nachman PH** and Falk RJ. Vasculitic Diseases of the Kidney. In: Schrier's Diseases Of The Kidney. 9th edition. Lippincott Williams & Wilkins, Philadelphia, PA 2012.
5. **Nachman PH**, Jennette, JC and Falk RJ. Chapter 31: Primary Glomerular Disease. In: Brenner's The Kidney. 9th edition W.B. Saunders Company, Philadelphia, PA. 2012.
6. Derebail, V and **Nachman PH**. In: Chapter 38: Vasculitides. In: Nephrology Secrets, 3rd Edition. Mosby. Edited by Edgar V. Lerma and Allen R. Nissenson, 2011. p. 271-277.
7. **Nachman PH**, Glassock RJ. Crescentic glomerulonephritis. In: Treatment of Primary Glomerulonephritis. Edited by Ponticelli C and Glassock RJ. Second edition. Oxford Clinical Nephrology Series. Oxford University Press. 2009: p. 399-435.
8. **Nachman PH**, Denu-Ciocca C. Vasculitides. In: Current Diagnosis and Treatment in Nephrology and Hypertension. Edited by Edgar V. Lerma, Allen R. Nissenson and Jeffrey S. Berns. Lange CURRENT series. McGraw-Hill 2009: p. 265-275.
9. **Nachman PH** and Falk RJ: Glomerulonephritis. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. 2nd Edition. Icon Learning Systems. 2009: p. 991-998.
10. **Nachman PH**: Nephrotic Syndrome. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. 2nd Edition. Icon Learning Systems. 2009: p. 999-1008.
11. Sanoff, S and **Nachman PH**: Hematuria. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. 2nd Edition. Icon Learning Systems. 2009: p. 962-967.
12. **Nachman PH**, Jennette, JC and Falk RJ. Primary Glomerular Disease. In: Brenner's The Kidney. 8th edition W.B. Saunders Company, Philadelphia, PA. 2008: p. 987-1066.
13. **Nachman PH**, Jennette, JC and Falk RJ. Vasculitic Diseases of the Kidney. In: Schrier's Diseases of the Kidney. 8th edition Lippincott Williams & Wilkins, Philadelphia, PA. 2007 Chapter 68: 1748-1775.
14. **Nachman PH** and Dooley MA. Systemic Lupus Erythematosus. In: Primer on Kidney Diseases 4th edition Edited by Arthur Greenberg 2005 Chapter 27, p. 234-240.
15. Falk RJ, Jennette, JC and **Nachman PH**. Primary Glomerular Disease. In: Brenner's The Kidney. 7th edition W.B. Saunders Company, Philadelphia, PA. Chapter 28, p. 1293-1380.
16. **Nachman PH** and Falk RJ: Glomerulonephritis. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. Icon Learning Systems. 2003: Chapter 114, p. 755-763.
17. **Nachman PH**: Nephrotic Syndrome. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. Icon Learning Systems. 2003: p. 771-778.
18. **Nachman PH**: Acute Renal Failure In Vasculitis. In: Acute Renal Failure. Edited by Molitoris and Finn. W.B. Saunders Company, Philadelphia, PA. 2001: Chapter 21, p. 275-291.
19. **Nachman PH**, Jennette, JC and Falk RJ. Vasculitic Diseases of the Kidney. In Schrier's Diseases of the Kidney. 7th edition Lippincott Williams & Wilkins, Philadelphia, PA. 2000; Chapter 68. 1911-1938.

20. **Nachman PH** and Falk RJ: Treatment of ANCA-Associated Small Vessel Vasculitis. In: Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney; edited by Brady HR and Wilcox. W.B. Saunders Company, Philadelphia, PA.1999: Chapter 23:158-164.
21. **Nachman PH**, Falk RJ and Jennette, JC: The Kidney in Systemic Disease. In: Clinical Nephrology, Dialysis and Transplantation. Edited by Malluch H.H., Sawaya B.P., Hakim R.M. and Sayegh M.H., Dusti-Verlag, Dr Karl Feistle, Deisenhofen, Germany. 1999: Chapter I.8 p. 1-42.
22. Falk RJ, Jennette, JC and **Nachman PH**. Primary Glomerular Disease. In: Brenner's The Kidney. 6th edition W.B. Saunders Company, Philadelphia, PA. 1996: Chapter 29, p. 1263-1349.
23. **Nachman PH** and Falk RJ: ANCA-Associated Small Vessel Vasculitis. In: Current Therapy in Nephrology and Hypertension, 4th edition. Edited by Glassock RJ. Mosby-Year Book, Philadelphia, PA. 1998: p. 161-165.
24. **Nachman PH**, Jennette JC, Falk RJ: Pathogenesis of Systemic Vasculitis. In: Rapidly Progressive Glomerulonephritis, edited by Rees AJ and Pusey CD, Oxford University Press, Oxford, London. 1998: Chapter 6:125-147.

Presentations

Invited Oral Presentations at *International Professional Meetings, Conferences, etc.*

1. **Nachman PH**, *Clinical Trial End Points for IgA Nephropathy: More than Just Creatinine*. American Society of Nephrology Kidney Week. San Diego, CA. Oct 25, 2018
2. **Nachman PH**, *The Kidney Health Initiative and IgAN*. 15th International Symposium on IgA Nephropathy, Buenos Aires, Argentina, Sept 28, 2018
3. **Nachman PH**, *ANCA Vasculitis*. Centre Hospitalier Universitaire, Universite de Nice, Nice, France, October 24, 2017
4. **Nachman PH**, *Glomerular Disease, Case Presentation and Discussion*. Nephrology Grand Rounds, American University of Beirut. Beirut, Lebanon. Via video conference, February 18, 2016
5. **Nachman PH**, *Autoimmunity in ANCA Vasculitis*. Advances in Targeted Therapy Conference. Palma de Mallorca, Spain, March 18, 2016
6. **Nachman PH**, *IgA Nephropathy*. Nephrology Grand Rounds, American University of Beirut. Beirut, Lebanon. Via video conference. December 3, 2015
7. **Nachman PH**, *Focal Segmental Glomerulosclerosis*. Lebanese Society of Nephrology and Hypertension. Beirut, Lebanon, October 16, 2015
8. **Nachman PH**, *Fibrillary Glomerulonephritis*. Lebanese Society of Nephrology and Hypertension. Beirut, Lebanon, October 16, 2015
9. **Nachman PH**, *ANCA Vasculitis*. American University of Beirut. Department of Medicine Grand Rounds. Beirut, Lebanon, October 12, 2015

10. **Nachman PH**, *Lupus Nephritis Case Discussion*. Nephrology Grand Rounds, American University of Beirut. Beirut, Lebanon. Via video conference, April 30, 2015
11. **Nachman PH**, *Biomarker in Glomerulopathy: False Dawn or New Horizon*. 12th Congress of the Arab Society of Nephrology and Renal Transplantation & 6th ISN-EMAN Update Course in Nephrology. Dubai, United Arab Emirates, December 11, 2014
12. **Nachman PH**, *Update on the role of Biological Agents in GN and Vasculitis*. 12th Congress of the Arab Society of Nephrology and Renal Transplantation & 6th ISN-EMAN Update Course in Nephrology. Dubai, United Arab Emirates, December 11, 2014
13. **Nachman PH**, *Treatment of Membranous Nephropathy*. Société Québécoise de Néphrologie. Montreal, Québec, Canada, May 8, 2014
14. **Nachman PH**, *Highlights of the ASN Glomerular and Parenchymal Disease*. European Renal Association/European Dialysis and Transplantation Association annual meeting, Istanbul, Turkey, May 19, 2013
15. **Nachman PH**, *ANCA Vasculitis*. University of Toronto, Canada, November 13, 2012
16. **Nachman PH**, *Parenchymal Disorders*. American Society of Nephrology Renal Week Ends, Berlin Germany, January 23, 2011
17. **Nachman PH**, *Vascularites à ANCA: Traitement des formes résistantes et récidivantes*. Journées de Néphrologie Hôpital Necker, Paris, France, April 24, 2006

Invited Oral Presentations at National Professional Meetings, Conferences, etc.

1. **Nachman PH**, *ANCA Vasculitis: What is the role of complement?* VA RC, Minneapolis, MN April 12, 2019
2. **Nachman PH**, *Pathogenesis of Glomerular Diseases. ASN Board Review Course and Update*, Chicago, IL, July 29, 2018
3. **Nachman PH**, *Membranous Nephropathy*, Nephrology Research Conference, Vanderbilt University, Nashville, TN, May 18, 2018
4. **Nachman PH**, *ANCA Vasculitis*, Nephrology Grand Rounds, Vanderbilt University, Nashville, TN, May 17, 2018
5. **Nachman PH**, *ANCA Vasculitis: Nephrology Grand Rounds*. Northwestern University, Chicago, IL, October 17, 2017
6. **Nachman PH**, *IgA Nephropathy*: Nephrology Grand Rounds. Northwestern University, Chicago, IL, October 17, 2017
7. **Nachman PH**, *Pathogenesis of Glomerular Diseases. ASN Board Review Course and Update*, Chicago, IL, July 30, 2017

8. **Nachman PH**, *ANCA Vasculitis*: Nephrology Grand Rounds. University of Minnesota, Minneapolis, MN, June 8, 2017
9. **Nachman PH**, *Clinical Conundrums in Nephritis: "Enough is Enough: When can I stop maintenance therapy for ANCA vasculitis in the post-RAVE era?"* National Kidney Foundation Meeting, Orlando, FL, April 19, 2017
10. **Nachman PH**, *Clinical Conundrums in Nephrotic Syndrome: "Thick or thin? Anticoagulation in the nephrotic syndrome"* National Kidney Foundation Meeting, Orlando, FL, April 19, 2017
11. **Nachman PH**, *Membranous Nephropathy: the fast pace of progress*. Brown University. Providence, RI, February 17, 2017
12. **Nachman PH**, *Pathogenesis of Glomerular Diseases. ASN Board Review Course and Update*, Chicago, IL, July 28, 2016
13. **Nachman PH**, *Clinical Developments in the Past 30 years in Glomerular Diseases*. Glomerular Disease Collaborative Network meeting. Chapel Hill, NC, April 16, 2016
14. **Nachman PH**, *ANCA Vasculitis*: Duke University, Durham, NC, April 6, 2016
15. **Nachman PH**, *Pathogenesis of Glomerular Diseases. ASN Board Review Course and Update*, Chicago, IL, July 26, 2015
16. **Nachman PH**, *ANCA vasculitis: Evolution of Pathogenesis and Treatment*. Emory University, Department of Medicine. Department of Medicine Grand Rounds, Atlanta, GA, April 14, 2015
17. **Nachman PH**, *Membranous Nephropathy: Asynchronous Progress?* Emory University, Division of Nephrology Grand Rounds, Atlanta, GA, April 14, 2015
18. **Nachman PH**, *Getting it Right in ANCA Vasculitis: The Right Test and the Right Treatment for the Right Patient*. National Kidney Foundation, Dallas, TX, March 26, 2015
19. **Nachman PH**, *Workshop: What Do You Know About Glomerular Disease? Case Presentations and Discussion (Session Co-Chair)*. National Kidney Foundation, Dallas, TX, March 26, 2015
20. **Nachman PH**, *ANCA vasculitis: Evolution of Pathogenesis and Treatment*. University of Washington, Division of Nephrology Grand Rounds, Seattle, WA, February 20, 2015
21. **Nachman PH**, *Membranous Nephropathy: Out of Sync Progress?* University of Washington, Division of Nephrology Grand Rounds, Seattle, WA, February 20, 2015
22. **Nachman PH**, *Diagnosis and Treatment of Small Vessel Vasculitis and Anti-Glomerular Basement Membrane Antibody Disease*. American Society of Nephrology Renal Week, Philadelphia, PA, November 11, 2014
23. **Nachman PH**, *Pathogenesis and Mechanisms of Glomerular Injury*. ASN Board Review Course and Update. Chicago, IL, August 3, 2014

24. **Nachman PH**, Case Based Panel Discussion: How to Treat Refractory Glomerular Diseases. ASN Board Review Course and Update. Chicago, IL, August 3, 2014
25. **Nachman PH**, Glomerulonephritides Case-Based Workshop. ASN Board Review Course and Update. Chicago, IL, August 3, 2014
26. **Nachman PH**, ANCA Vasculitis: National Kidney Foundation Annual Meeting, Las Vegas, NV, April 22, 2014
27. **Nachman PH**, FDA-NephCure Patient Reported Outcomes Workshop; Silver Spring, MD, March 12, 2014
28. **Nachman PH**, Treatment of Membranous Nephropathy. American Society of Nephrology Renal Week, Atlanta, GA, November 5, 2013
29. **Nachman PH**, Pathogenesis and Mechanisms of Glomerular Injury. ASN Board Review Course and Update. Chicago, IL, August 10, 2013
30. **Nachman PH**, Case Based Panel Discussion: How to Treat Refractory Glomerular Diseases. ASN Board Review Course and Update. Chicago, IL, August 10, 2013
31. **Nachman PH**, Glomerulonephritides Case-Based Workshop. ASN Board Review Course and Update. Chicago, IL, August 10, 2013
32. **Nachman PH**, Membranous Nephropathy. University of Iowa. Iowa City IA, June 18, 2013
33. **Nachman PH**, Renal Biopsy: Clinical Correlations. Clinical Discussant. American Society of Nephrology Renal Week, San Diego, CA, November 3, 2012
34. **Nachman PH**, Case Studies in Glomerular Disease. American Society of Nephrology Renal Week, San Diego, CA, October 31, 2012
35. **Nachman PH**, Diagnosis and Treatment of Small Vessel Vasculitis and Anti-Glomerular Basement Membrane Disease. American Society of Nephrology Renal Week, San Diego, CA, October 31, 2012
36. **Nachman PH**, Treatment of Membranous Nephropathy. American Society of Nephrology Renal Week, San Diego, CA, October 30, 2012
37. **Nachman PH**, Pathogenesis and Mechanisms of Glomerular Injury. ASN Board Review Course and Update. Chicago, IL, August 25, 2012
38. **Nachman PH**, Case Based Panel Discussion: How to Treat Refractory Glomerular Diseases. ASN Board Review Course and Update. Chicago, IL, August 25, 2012
39. **Nachman PH**, Glomerulonephritides Case-Based Workshop. ASN Board Review Course and Update. Chicago, IL, August 25, 2012
40. **Nachman PH**, Glomerular Diseases. American Society of Nephrology Renal Week Ends. Washington, DC, April 29, 2012
41. **Nachman PH**, Small Vessel Vasculitis, Vasculitis Foundation, Chicago, IL, April 21, 2012

42. **Nachman PH**, Parenchymal Disorders. American Society of Nephrology Renal Week Ends. Dallas, TX, March 7, 2012
43. **Nachman PH**, Glomerulonephritis Update: Diagnosis and Therapy. American Society of Nephrology Renal Week Diagnosis and Treatment of Small Vessel Vasculitis and Anti-GBM disease, Philadelphia, PA, November 2011
44. **Nachman PH**, Glomerulonephritis Update: Diagnosis and Therapy. American Society of Nephrology Renal Week GN Treatment Guidelines: Small Vessel Vasculitis, Philadelphia, PA, November 2011
45. **Nachman PH**, Clinico-Pathologic Case Presentations. Florida Society of Nephrology, September 18, 2011
46. **Nachman PH**, Translation of Pathogenic Understanding to Novel Therapies. 15th International Vasculitis & ANCA Workshop, UNC Chapel Hill, NC, May 17, 2011
47. **Nachman PH**, Wegener's granulomatosis versus microscopic polyangiitis: Do the names translate into meaningful differences in approach to therapy? Combined Nephrology Rheumatology Grand Rounds: Massachusetts General Hospital, March 15, 2011
48. **Nachman PH**, Parenchymal Disorders. American Society of Nephrology Renal Week Ends. Dallas, TX, March 4, 2011
49. **Nachman PH**, Understanding Lab Tests for patients with vasculitis. Vasculitis Foundation. NC Chapter of Vasculitis Foundation Meeting. Durham, NC, January 2011
50. **Nachman PH**, ANCA small vessel vasculitis. American Society of Nephrology Renal Week 2010, Denver, CO, November 2010
51. **Nachman PH**, Thrombotic microangiopathies. American Society of Nephrology Renal Week 2010, Denver, CO November 2010
52. **Nachman PH**, Diagnosis and Treatment of Small Vessel Vasculitis American Society of Nephrology Renal Week 2010, Denver, CO November 2010
53. **Nachman PH**, Case-based discussion: Nephritides American Society of Nephrology Renal Week 2010, Denver, CO November 2010
54. **Nachman PH**, Hematuria. Medicine Grand Rounds. Danville VA, October 21, 2010
55. **Nachman PH**, Understanding Lab Tests for patients with vasculitis. Vasculitis Foundation. NC Chapter of Vasculitis Foundation Meeting. Long Beach, CA, August 1, 2010
56. **Nachman PH**, Membranous Nephropathy. Glomerular Disease Collaborative Network, The William and Ida Friday Center, Chapel Hill, NC, May 2010
57. **Nachman PH**, IgA Nephropathy. Glomerular Disease Collaborative Network, The William and Ida Friday Center, Chapel Hill, NC, May 2010
58. **Nachman PH**, Targeting Complement in ANCA vasculitis. Glomerular Disease Collaborative Network, The William and Ida Friday Center, Chapel Hill, NC, May 2010

59. **Nachman PH**, Small vessel vasculitis. National Kidney Foundation Spring meeting. Orlando FL, April 2010
60. **Nachman PH**, Glomerulonephritis Update: Diagnosis and Therapy. Diagnosis and Treatment of Small Vessel Vasculitis, American Society of Nephrology Renal Week , San Diego, CA November 2009
61. **Nachman PH**, Glomerulonephritis Update: Diagnosis and Therapy. Thrombotic microangiopathies, American Society of Nephrology Renal Week , San Diego, CA November 2009
62. **Nachman PH**, ANCA Small Vessel Vasculitis. American Society of Nephrology Renal Week , San Diego, CA November 2009
63. **Nachman PH**, Thrombotic . National Kidney Foundation, SC, April 2009
64. **Nachman PH**, Glomerulonephritis Update: Diagnosis and Therapy. Diagnosis and Treatment Small Vessel Vasculitis. American Society of Nephrology Renal Week , Philadelphia, PA November 2008
65. **Nachman PH**, Glomerulonephritis Update: Diagnosis and Therapy. Nachman, PH, Glassock, R, Pusey, C. Treatment Issues in Rapidly Progressive Glomerulonephritis: Variations on Transatlantic Themes. American Society of Nephrology Renal Week , Philadelphia, PA November 2008
66. **Nachman PH**, Nachman, PH, Radhakrishnan, J. Management Cases in Lupus Nephritis, Viral Glomerulonephritis and Dysproteinemias. American Society of Nephrology Renal Week , Philadelphia, PA November 2007
67. **Nachman PH**, Glomerular Vascular and Tubulointerstitial Diseases, NephSAP volume 7, number 3. American Society of Nephrology Renal Week, San Francisco, CA November 2007
68. **Nachman PH**, American Society of Nephrology. ClinicoPathologic Conference. Discussant. San Francisco, CA November 2007
69. **Nachman PH**, Update on the therapy of ANCA vasculitis. National Kidney Foundation, SC and GA chapters. Hilton Head, SC, September 2007
70. **Nachman PH**, ANCA vasculitis: Therapeutic Approach. New York Society of Nephrology. New York, NY, February 13, 2007
71. **Nachman PH**, Advances in the Treatment of ANCA Vasculitis. American Society of Nephrology Renal Week San Diego, CA, November 18, 2006
72. **Nachman PH**, New Therapies in Vasculitic Glomerulonephritis. American Society of Pediatric Nephrology. Washington DC, May 15, 2005
73. **Nachman PH**, The Utility of Serial ANCA testing in predicting relapse. American Society of Nephrology Renal Week, St. Louis, MO October 30, 2004
74. **Nachman PH**, Ethnic and Gender Disparities in the progression of chronic kidney disease: Glomerular disease-related chronic kidney disease. American College of Clinical Pharmacy, Albuquerque, NM, October 21, 2002

75. **Nachman PH**, Introduction to vasculitides affecting the kidney. American Nephrology Nurses Association (ANNA). NC Chapter, January 21, 1999
76. **Nachman PH**, ANCA-Small Vessel Vasculitis: Outcome and Relapse. Stanford University, November 1998

Invited Oral Presentations at *Local/Institutional and Regional Professional Meetings, Conferences, etc.*

1. **Nachman PH**, Transplant Surgery Conference, University of Minnesota, Minneapolis, MN. “IgA Nephropathy and Kidney Transplantation” April 17, 2019
2. **Nachman PH**, Division of Renal Diseases and Hypertension Grand Rounds: “Nephrology Clinical Research the U., the Twin Cities and the State” April 4, 2019
3. **Nachman PH**, Department of Medicine Research Conference, University of Minnesota, Minneapolis, MN. “Surrogate Endpoints for Nephrology Drug Development” March 4, 2019
4. **Nachman PH**, Hennepin County Medical Center Medicine Grand Rounds, Minneapolis MN. “ANCA Vasculitis” February 28, 2019
5. **Nachman, PH**, Rheumatology Citywide Conference, University of Minnesota, Minneapolis, MN. “ANCA Vasculitis 25 years of progress”
6. **Nachman PH**. Nephrology Journal Club. Discussion of De Rosa M et al, *Kidney International* 2018;94:788-794. October 16, 2018
7. **Nachman, PH**, Nephrology Grand Rounds, University of Minnesota, Minneapolis, MN. “IgA Nephropathy”. September 6, 2018
8. **Nachman, PH**, Rheumatology Grand Rounds, University of Minnesota, Minneapolis, MN. “ANCA Vasculitis and Complement Activation”. April 25, 2018
9. **Nachman, PH**, Rheumatology Grand Rounds, University of North Carolina, Chapel Hill, NC. “ANCA Vasculitis: a 25 year retrospective”. March 2, 2018
10. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Nobody knew IgA Nephropathy could be so complicated” April 25, 2017
11. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center (CPC), Chapel Hill, NC “Drug-Associated Thrombotic Microangiopathy and Vasculitis” December 10, 2015
12. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “IgA Nephropathy” September 2, 2015
13. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Membranous Nephropathy” March 11, 2015
14. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Vaso-occlusive disease in kidney disease” April 30, 2014

15. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Update on Glomerular Disease” February 20, 2013
16. **Nachman, PH**, Rheumatology Grand Rounds, University North Carolina, Chapel Hill, NC “Prophylactic Anticoagulation in Nephrotic Syndrome” September 21, 2012
17. **Nachman, PH** and Darling, J., Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Hepatitis C-related kidney disease” May 9, 2012
18. **Nachman, PH** 36th Annual Internal Medicine Conference: “Kidney Function in the Elderly”, University North Carolina, Chapel Hill, NC ,March 16, 2012
19. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Membranous Nephropathy” March 7, 2012
20. **Nachman, PH**, Vasculitis Foundation. Regional Vasculitis Patient and Family Symposium. Chapel Hill, NC. “Standard Treatment of Small Vessel Vasculitis”; “The Kidney”, May 14, 2011
21. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC “Morbidity and Mortality Conference. Complications of a Drug Interaction” May 12, 2011
22. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “MPA vs Wegener’s granulomatosis” April 20, 2011
23. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Update on GN at the ASN 2010 part 2” March 2, 2011
24. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Update on GN at the ASN 2010 part 1” February, 2011
25. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Cognitive Impairment and Kidney Disease” October 1, 2008
26. **Nachman, PH**, Rheumatology Grand Rounds, University North Carolina, Chapel Hill, NC “ANCA vasculitis: Therapeutic Approach” April 4, 2008
27. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC “Morbidity and Mortality Conference. Life-Threatening Hemoptysis” January 10, 2008
28. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “ANCA and predictors of outcome” December 5, 2007
29. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC “Nephrogenic Fibrosing Dermopathy” May 10, 2007
30. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Cystatin C” December 13, 2006
31. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “On the long term management of ANCA vasculitis” April 5, 2006

32. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Costimulatory Blockade in Autoimmunity” October 19, 2005
33. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Gadolinium and Nephrotoxicity” March 30, 2005
34. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC "Of Cysts and Cilia" an update on polycystic kidney disease” December 10, 2003
35. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC "le Podocyte et vous": a review of the cell-physiology of the podocyte” May 28, 2003
36. **Nachman, PH**, Rheumatology Grand Rounds, University North Carolina, Chapel Hill, NC "Lupus nephritis: myths, limitations, and pitfalls" April 22, 2003
37. **Nachman, PH**, 27th Annual Internal Medicine Conference: “Approach to the diagnosis of proteinuria”, University North Carolina, Chapel Hill, NC " March 27, 2003
38. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC "But what about ANCA: a look at the role of MPO in endothelial dysfunction" October 16, 2002
39. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC “Department of Medicine CPC” September 20, 2002
40. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC " Thrombotic Microangiopathy after Transplantation " March 13, 2002
41. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC “Diabetic Nephropathy” December 13, 2001
42. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Diabetes Mellitus: the new molecular biology " September 19, 2001
43. **Nachman, PH**, 25th Annual Internal Medicine Conference: “Microscopic Hematuria; the Nephrologist’s Perspective”, University North Carolina, Chapel Hill, NC March 9, 2001
44. **Nachman, PH**, Rheumatology Grand Rounds, University North Carolina, Chapel Hill, NC, “ANCA-small vessel vasculitis; Therapeutic issues”. February 20, 2001
45. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Recurrent Glomerular Disease after Renal Transplantation " October 25, 2000
46. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC “Department of Medicine CPC” May 30, 2000
47. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC “The Many Faces of FSGS” February 03, 2000
48. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC “Focal segmental glomerulosclerosis permeability factor " January 12, 2000
49. **Nachman, PH**, 23rd Annual Internal Medicine Conference: “Mechanisms of Salt and Water Retention”, University North Carolina, Carolina Population Center, Chapel Hill, NC April, 16, 1999.

50. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC "Scleroderma kidney disease " November 11, 1998
51. **Nachman, PH**, Internal Medicine Grand Rounds, University North Carolina, Carolina Population Center, Chapel Hill, NC "Department of Medicine CPC" February 17, 1998
52. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC "Cryoglobulins and nephropathy " January 28, 1998
53. **Nachman, PH**, Nephrology Grand Rounds, University North Carolina, Chapel Hill, NC "Pathogenesis of TTP " April 16, 1997

Peer-reviewed Oral Presentations at Professional Meetings, Conferences, etc. : Listed above

Poster Abstract Presentations at Professional Meetings, Conferences, etc.: Listed above under abstract

TEACHING AND CURRICULUM DEVELOPMENT

Course / Lecture List:

University North Carolina

Invited Continuing Education Lectures

- | | |
|---|----------------|
| 36th Annual Internal Medicine Conference: "Kidney Function in the Elderly" | March 16, 2012 |
| 27th Annual Internal Medicine Conference: "Approach to the diagnosis of proteinuria" | March 27, 2003 |
| 25th Annual Internal Medicine Conference: "Microscopic Hematuria; the Nephrologist's Perspective" | March 09, 2001 |
| 23rd Annual Internal Medicine Conference: "Mechanisms of Salt and Water Retention" | April 16, 1999 |

American Society of Nephrology

- | | |
|---|---------------|
| Maintenance of Certification Post Graduate Education Course: Glomerular Disease | November 2010 |
| Maintenance of Certification Post Graduate Education Course: Glomerular Vascular and Tubulointerstitial Diseases, NephSAP volume 7, number 3. | November 2007 |

University of Minnesota

Nephrology Grand Rounds: responsible for organization, administration and review for CME accreditation of weekly academic conference. September 2018 - present

ADVISING AND MENTORING

Graduate Student Activities

Graduate Supervision Committees

1.
Dr Vimal Derebail

NIH T32 Training Grant in Renal Epidemiology.
7/2007-7/2009.
Role: Co-mentor.

2.
Dr Scott Sanoff
NIH T32 Training Grant in Renal Epidemiology.
7/2006-7/2008.
Role: Co-mentor.

3.
Dr. Keisha Gibson
NIH T32 Training Grant in Renal Epidemiology.
7/2006 – 6/2008
Role: Co-mentor and member of Scholarly Oversight Committee.

Post-doctoral fellows supervised

Post-Doctoral Research: Lama Ghazi, MD (PhD candidate)
June 2018 – present

Dr Ghazi is currently pursuing a PhD in Epidemiology at the University of Minnesota, under the mentorship of Dr Drawz. She is also developing a translational research project on the association of IgA Nephropathy and Inflammatory Bowel Disease under my supervision.

Post-Doctoral Clinical and Research Fellow: Monica Reynolds, MD
July 2017 – July 2018

Dr Reynolds is currently pursuing a Masters of Science in Clinical Research (MSCR) at the UNC Billings School of Public Health. Her research interests are focused on the health of women with kidney disease.

1.
Post-Doctoral Clinical and Research Fellow: Harpreet Singh, MD
July 2017 – June 2018

Dr Singh pursued a post-doctoral clinical and research fellowship in glomerular diseases and vasculitis (“GN fellowship”). Her research interest are in studying the decision process and clinical impact of repeat kidney biopsy in patients with systemic lupus erythematosus and lupus nephritis. Dr Singh is currently an Assistant Professor, Division of Nephrology, Duke University, Durham, NC

2.
Post-Doctoral Clinical and Research Fellow: Manish Saha, MD
April 2017 – June 2018

Dr Saha pursued a post-doctoral clinical and research “GN fellowship” after completing his clinical nephrology fellowship. His main research interest is in elucidating differences and pathogenic mechanisms of IgA nephropathy secondary to gastrointestinal and hepatic disease. Dr Saha is currently an Assistant Professor, Division of Nephrology, University of North Carolina, Chapel Hill, NC.

3. □
Post-Doctoral Clinical and Research Fellow: YoungHo Kim MD
July 2016-June 2017

Dr Kim is pursuing his “GN fellowship” after having completed his nephrology clinical fellowship. His main research topic pertains to the nature, treatment and outcomes of glomerular diseases in patients with underlying diabetes. Dr Kim is currently a practicing nephrologist in Tacoma, WA

4. □

Post-Doctoral Clinical and Research Fellow: Shannon Mahoney MD, MPH

July 2016-present

Dr Mahoney is pursuing a post-doctoral research fellowship as part of her fellowship in nephrology. The main research topic pertains to the analysis, development and use of Patient Reported Outcome tools in nephrology, focusing on patients with glomerular diseases. Dr Mahoney (now Murphy) is currently an instructor in the Division of Nephrology at the University of North Carolina, Chapel Hill, NC

5. □

Post-Doctoral Research Fellow: Dr Elizabeth Brant. MD

July 2013-July 2015.

Dr Brant is the recipient of the first Vasculitis Foundation Fellowship award for 2 years. Dr Brant's research will focus on the clinical predictors and the mechanisms of thrombosis in patients with ANCA vasculitis.

7.

Masters of Science of Epidemiology: Dr Louis Philippe Laurin MD

McGill University

Co-mentor for thesis: Dr Laurin will continue his work on the factors influencing choice of therapy, the predictors of outcome, and comparative analysis of treatment effectiveness in FSGS.

8. □

Post-Doctoral Research Fellow: Dr Louis Philippe Laurin MD

November 2011- July 2013

Dr Laurin completed a 2-year research fellowship in Glomerular Diseases.

Dr Laurin's main research projects are:

a. Clinical outcomes and their predictive factors in Focal Segmental Glomerulosclerosis (FSGS). His initial work is focused on Collapsing FSGS. A manuscript has been submitted to *Kidney International* in October 2013:

Laurin LP, Gasim AM, Derebail VK, McGregor JAG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH. Collapsing and Not Otherwise Specified Focal Segmental Glomerulosclerosis Have Similar Response to Immunosuppressive Therapy. Submitted *Kidney Int.* 2013.

b. The effect of Hydroxyurea treatment on proteinuria in patients with Sickle Cell disease. The results of this work are presented in a manuscript accepted for publication:

Laurin LP, Nachman PH, Desai PC, Ataga KI, Derebail VK. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. *Nephrol Dialysis Transplant.* 2013. In Press.

9.

Post-Doctoral Visiting Scholar: Dr Taewoo Lee MD.

March 2010 – 2015.

Dr Lee's research projects include a decision analysis of prophylactic anticoagulation in patients with idiopathic membranous nephropathy based on a very large cohort of patients combined from the Glomerular Disease Collaborative Network and the Toronto Glomerulonephritis Network. His second project is an assessment of the outcomes of patients with ANCA vasculitis presenting with severe renal failure, and analysis of factors determining the likelihood of recovery of renal function.

His third project is a detailed analysis of cardiovascular morbidity and mortality associated with the nephrotic syndrome, and membranous nephropathy in particular. This analysis is based on the large updated cohort of patients combined from the Glomerular Disease Collaborative Network and the Toronto Glomerulonephritis Network.

10.

Shannon Mahoney, MPH

September 2010- June 2011

Mentored and served as first reader for Ms Mahoney's Master Paper in partial fulfillment of requirements for Master in Public Health at the UNC School of Public Health. The title of her project is "Factors Influencing Choice of Treatment in Idiopathic Membranous Nephropathy".

11.

Post-Doctoral Visiting Scholar: Dr Sophia Lionaki MD

September 2005 – December 2007

Dr Lionaki spent a little more than two years as a visiting scholar focusing on epidemiologic studies of glomerular diseases and vasculitis. Her efforts have resulted in several manuscripts that are either published or in preparation. She is currently an attending nephrologist at the Laiko General Hospital, Athens, Greece.

12.

Post-Doctoral Visiting Scholar: Dr Regulo Valdes MD

May 2006 – June 2007

Dr Valdes spent a year as a visiting scholar from Panama. His work has focused on glomerular diseases and transplantation. He also developed a novel approach to measure microparticles as they pertain to kidney transplant recipients. He is currently on faculty at the University of Panama, and an attending nephrologist at the Complejo Hospitalario Metropolitano, Panama City, Republic of Panama

13.

Post-Doctoral Research Fellow: Dr Uta Erdbruegger MD,

October 2001 to October 2003.

Research fellowship in nephrology after completing her residency in Internal Medicine at Tulane University. She completed her clinical fellowship in September 2004. Dr Erdbruegger is currently on faculty in the Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA.

14.

Post-Doctoral Research Fellow: Dr Thomas Hellmark, PhD from the University of Lund, Sweden.

July 2000 to July 2001 Dr Hellmark worked in my laboratory on the genetic characterization of variable region gene expression of anti-MPO B cells from patients with MPO-ANCA small vessel vasculitis, as well as on the epitope mapping of human MPO. Dr Hellmark is currently on Faculty at the University of Lund, Sweden.

15.

PhD candidate: Hitendra Jethwa. Dr Jethwa worked in my laboratory on a project I designed and initiated. I supervised and provided guidance in his work on the “Molecular Characterization of the Spontaneous Anti-Myeloperoxidase Autoantibody Response in SCG/Kj Mice”. Dr Jethwa was granted a doctorate degree on December 31, 1999.

CLINICAL SERVICE

Clinical Service Responsibilities

University of Minnesota

- 1- Attending, Inpatient Nephrology Consult Teaching Service. 4 weeks per year
- 2- Attending, Inpatient Nephrology Consult APP Service. 4 weeks per year
- 3- Outpatient Nephrology Clinic: ½ day clinic per week
- 4- Inpatient Consult Weekend Call: 5 weekends + 3 weekends “short call”

University of Carolina. (Until March 2018)

- 5- Attending, Inpatient Nephrology Service (Primary Service), (1 resident, 2 interns, 2-4 medical students, 20 beds). 6-8 weeks per year
- 6- Attending, Inpatient Nephrology Service (2 fellows, 1-2 residents, 1-2 medical students, average census 45 patients/day). 6-8 weeks per year
- 7- Nephrology GN and Vasculitis Clinic. 1 full day/week (8 hours, average 17 patients)
- 8- Inpatient Nephrology Primary Service + Consult Service weekend call : 6 weekends/year
- 9- Outpatient Peritoneal Dialysis clinic: 6-8 full day clinics/year (2010-2018)
- 10- Outpatient Incenter Hemodialysis: 4-10 weeks /year (1996- 2010)

PROFESSIONAL SERVICE AND PUBLIC OUTREACH

Service To The Discipline/Profession/Interdisciplinary Area(s)

National Institute of Health

Ad hoc member, October 2017

National Institute of Diabetes, Digestive and Kidney Disease. Pathology of Kidney Disease

Ad hoc member, July 2018

National Institute of Diabetes, Digestive and Kidney Disease. Pathology of Kidney Disease

Ad hoc member, February 2019

National Institute of Diabetes, Digestive and Kidney Disease. Special Emphasis review

Kidney Health Initiative

Co-Chair, 2016-present

Surrogate Endpoint in IgA Nephropathy Working Group

Editorships/Journal Reviewer Experience

Manuscript reviewer or major medicine, nephrology and rheumatology journals:

American Journal of Kidney Disease	1996-present
Arthritis and Rheumatology	1996-present
Clinical Journal of the American Society of Nephrology	1996-present
JAMA	1996-present
Journal of the American Society of Nephrology	1996-present
Kidney International	1996-present

Nephrology Self-Assessment Program (NephSAP)

Associate Editor: 2007- 2014

NephSAP Contributions:

1. **Nachman PH** and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program.(NephSAP) .J Am Soc Nephrol. NephSAP, 2014 online publication.
1. Clark W, Derebail VK and **Nachman PH**. Co editor, Vaso-occlusive Diseases of the Kidney Nephrology Self Assessment Program (NephSAP). January 2014 Online publication
2. **Nachman PH** and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self Assessment Program.(NephSAP). 2012; 11:140-217
3. Nephrology Self Assessment Program.(NephSAP). 2010; 9:123-200
4. **Nachman PH** and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self Assessment Program.(NephSAP). 2008;7,131-207

Journal Club

UNC, Division of Nephrology Journal Club
1996-2018: yearly 2-3 presentations;
Coordinator: 2002-2012.

Program review experience

ASN Highlights

ASN Highlights are programs offered every year to provide a summary of the previous ASN Kidney week. Each lecture is 90 minutes long and covers a selection of the presentations pertaining to glomerular and interstitial diseases.

Course Moderator. Mumbai, India	3/4-5/2017
Parenchymal Disorders. Philadelphia, PA	2/23/2013
Parenchymal Disorders. Washington, DC	4/29/2012
Parenchymal Disorders. Dallas, TX	3/4/2012
Parenchymal Disorders. Dallas, TX	2/13/2011
Parenchymal Disorders. Berlin, Germany	1/23/2011

Organization of conferences, workshops, panels, symposia

Glomerulonephritis Update: Diagnosis and Therapy.

Course Co-Chair:

A two-day course entirely focused on the pathogenesis, pathology and treatment of glomerular diseases. Attended by 450-500 nephrologists from the US and the world. This is consistently the largest in-depth course offered by the American Society of Nephrology

American Society of Nephrology Renal Week 2014:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy. Diagnosis and Treatment of Small Vessel Vasculitis and Anti–Glomerular Basement Membrane Antibody Disease

American Society of Nephrology Renal Week 2013:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy. Treatment of Membranous Nephropathy

American Society of Nephrology Renal Week 2012:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy. Diagnosis and Treatment of Small Vessel Vasculitis and anti-GBM Disease Treatment of Membranous Nephropathy

American Society of Nephrology Renal Week 2011:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy. Diagnosis and Treatment of Small Vessel Vasculitis and Anti-GBM disease GN Treatment Guidelines: Small Vessel Vasculitis

American Society of Nephrology Renal Week 2010:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy.
Thrombotic microangiopathies
Diagnosis and Treatment of Small Vessel Vasculitis
Case-based discussion: Nephritides
Maintenance of certification course: Glomerular Disease

American Society of Nephrology Renal Week 2009:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy.
Diagnosis and Treatment of Small Vessel Vasculitis
Thrombotic microangiopathies

American Society of Nephrology Renal Week 2008:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy. Treatment Issues in Rapidly Progressive Glomerulonephritis: Variations on Transatlantic Themes. Patrick Nachman, Richard Glassock, and Charles Pusey

American Society of Nephrology Renal Week 2007:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy. 10/31-11/1/2007

Maintenance of Certification; Post Graduate Education Course. Glomerular Vascular and Tubulointerstitial Diseases, NephSAP volume 7, number 3.

ClinicoPathologic Conference. Discussant.

ANCA Small Vessel Vasculitis

Management Cases in Lupus Nephritis, Viral Glomerulonephritis, and Dysproteinemias.
Patrick Nachman and Jai Radhakrishnan

Treatment Issues in Rapidly Progressive Glomerulonephritis: Variations on Transatlantic Themes. Patrick Nachman, Richard Glasscock, and Charles Pusey

Committee memberships

Member, Faculty at Large Committee, University of North Carolina 2013-2016

American Society of Nephrology Post-Graduate Education Committee

Chair: 9/2013-present

As chair of the PGE committee, I am responsible for the development, organization and implementation of clinical continuing education programs at the yearly conference of the American Society of Nephrology (ASN Kidney Week) which draws about 13000 attendees from around the world. This includes 40 Clinical Practice Sessions (2 hours each), 13 In-Depth Nephrology Courses (1 or 2 day courses which attract about 2000 attendees), and 13-15 Educational Sessions (1 hour sessions which attract 300-500 attendees each).

Chair-elect: 9/2012- 9/2013

Member: 2007- 2012
Contributed each year to the organization of Clinical Nephrology Conferences and Educational Symposia.

Renal Week

Course Co-Chair: 9/2007-2014

A two-day course entirely focused on the pathogenesis, pathology and treatment of glomerular diseases. Attended by 450-500 nephrologists from the US and the world. This is consistently the largest in-depth course offered by the American Society of Nephrology

Glomerular Disease Advisory Committee

Member: 2008-2014

Member, General Clinical Research Center Scientific Advisory Committee, 1997-2012
University of North Carolina

Member, Office of Human Research Ethics: Biomedical Institutional Review Board, University of North Carolina 2002-2009

Member, FSGS Internal Medicine Committee, NIH FSGS Trial 2007-2009

Member, NIAID: Special Emphasis Panel reviewing applications in response to 1998

Service to the University/Medical School/Department

University of Minnesota [indicate dates of service activities]

University-wide service

Medical School Service and Intercollegiate Service

Master Clinician Track Promotions Committee, Member. August 2018-present.

Department/Unit Service

Search Committee: Minneapolis VA Medical Center, Search committee for Division of Nephrology Director.

Service to the University/Medical School/Department

University of North Carolina

Medical School Service and Intercollegiate Service

Faculty At Large Committee: August 2013-2016

Office of Human Research Ethics: Biomedical Institutional Review Board: March 2002-2009

General Clinical Research Center Scientific Advisory Committee: 1997-2012

Department/Unit Service

Department of Medicine tenure *Promotions committee*

Community Outreach Activities

Kidney Education Outreach Program, University of North Carolina. Served as Deputy Director of the UNC Kidney Center. I was responsible for, and oversaw the conduct of the UNC KEOP which provided education on kidney disease, as well as conducted screening of hypertension, proteinuria, hematuria, and kidney disease in underserved communities in North Carolina.

National Kidney Foundation KEEP community screening for kidney disease. Minneapolis, MN. Oct 5, 2018